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Summary 
 
Within the field of Regenerative Medicine stem cells hold great potential for treating 
currently incurable diseases. One of these stem cells of interest is the Mesenchymal Stromal 
Cell (MSC). Major sources for MSCs are adipose tissue and bone-marrow although recently 
it has been proven that MSCs can also be isolated from different tissues such as liver (Pan 
Q, 2011), pancreas (Zanini C, 2011), muscles (Kisiel AH, 2011) etc. MSCs, with their well-
known anti-inflammatory activity, are ideal for treatment of acute or fulminant liver 
diseases for which the only treatment option is liver transplantation. Moreover this 
multitude of source opportunities makes it possible to perform autologous treatment of 
patients with minimally invasive approaches. Due to the low number of available liver 
transplants, alternative (curative) treatments are necessary. Although the use of MSCs in 
mouse models seems promising, the lack of a large animal model limits the application of 
MSCs in a human clinical setting. For years the liver research group at the CSCA (Clinical 
Sciences for Companion Animals, Utrecht, The Netherland) has been investigating the dog 
as a large model animal. This research showed that canine liver diseases and regenerative 
mechanisms are highly comparable to their human counterparts. Up to now possibilities of 
treatments for liver diseases in the dog are limited, for this reason MSCs hold a great 
potential as a possible population for cell therapies. Prerequisite for the use of MSCs is their 
characterisation before clinical application. For this we started with the optimization of a 
protocol for the isolation of LMSCs, starting either from a wedge liver biopsy or from an 
intra-lobular perfused fraction. The focus of the second part was the characterisation of 
canine MSCs derived from adipose tissue (ASCs), bone-marrow (BMSCs), and liver (LMSCs). 
All cell types are in culture at the department of CSCA and multiple samples have been 
stored (liquid nitrogen). Characterization of the MSCs has been performed according to 
Dominici et al. (Horwitz EM & Therapy., 2005). The characterization started with gene-
expression profiling of the different fractions (ASCs, BMSCs, and LMSCs). Canine specific 
primers have been designed and optimized and specificity tested by sequencing of the PCR 
product. Results indicated that all MSC fractions are positive for standard MSC markers (e.g. 
CD90, CD105) and negative for markers of haematopoietic cells, macrophages, endothelial 
cells (e.g. CD45). After this a selection of canine specific antibodies directed against Cluster 
of Differentiation (CD) markers (CD45-, CD90+, CD105+, CD29+, CD166+) has been optimised 
for Fluorescent Activated Cell Sorting (FACS) analysis. Finally the resulting LMSCs profile, for 
both qPCR and FACS analysis, has been compared to the human MSC profile (Fouraschen 
SM, Secreted factors of human liver-derived mesenchymal stem cells promote liver 
regeneration early after partial hepatectomy., 2012). This research will be the basis on 
which clinically applied mesenchymal stromal cells can become a reality within the 
veterinary field. This will, in turn, provide the necessary information to apply these cells in 
human clinics. 
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Introduction 
 
Stem cells 
 
The research of stem cells and their possible manipulation for clinical purposes is nowadays, 
in my opinion, one of the most interesting and fascinating topics in Molecular Biology. Two 
main characteristics are required to define a stem cell: the ability to self-renew which 
ensures stem cells to be able to reconstitute their own population, and the ability to 
differentiate into different types of cells (Anderson DJ, 2001). The differentiation capacity 
of stem cells is well known as cell potency and different types of stem cells are hierarchically 
clustered based on the level of differentiation potency (Fig. 1). Totipotency (being able to 
produce both the embryonic tissues and its annexes - (Surani MA, 2007)) for example is 
characteristic only of the zygote cell and few a daughter cells in the first stages of 
development. Between fertilization and the beginning of segmentation, the cell potency 
slowly reduces trough the cells decision called lineage events. Pluripotent stem cells for 
example, have lost their ability to form the extra-embryonic tissues such as the placenta 
and the yolk sac, but are still able to form the three germ layers of the developing embryo 
(endoderm, mesoderm, and ectoderm). Pluripotent cells exist in the inner cell mass of the 
blastocyst and are a source of human embryonic stem cell (hESC) lines (JC., 2008). 
 
 
Figure 1: Hierarchically classification of stemness potential of stem cells. ES; embryonic stem cells, 
iPS; induced pluripotent stem cells.  
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This classical view of a hierarchical classification of the stem cell potency is most of time still 
applicable to study the in vivo behavior of these cells. However, recently the Nobel Prize 
Yamanaka has proven the possibility to convert potentially any type of somatic cell into a 
so called Induced Pluripotent Stem (IPS) cell by using a lentiviral overexpression system with 
a cocktail of transcription factors which are highly expressed in embryonic stem cells 
(Takahashi K, 2007). Due to this discovery scientist have now started to interfere directly 
with the cell potential as we are now starting to understand how to move from any kind of 
somatic cell to another without the need of stepping trough a stem cell like stage 
(Transdifferentiation) (Ladewig J, 2013).  
This new prospective of possibilities capsize the point of view that for years has guided 
research on stem cells, developmental steps are no longer the only path we can follow, now 
we can play with the infinite networks combination and push the cells towards a new 
artificial-designed path (commitment) expecting virtually everything. To clarify this idea an 
easy representation is the Weddington’s model of the epigenetic changes (Figure 2) that 
occur during the commitment of any (stem)-cell, the marble exemplify a cell going through 
its differentiation pathway. In this model Weddington imagines the changes in the 
epigenetic signature as different downhill roads; the marble (the cell), because of the 
gravity, is able only to roll down entering a specific road without the option of going up 
again. This model fits the mechanisms that rule the development but technologies such as 
reprogramming nowadays allow us to redirect the paths that the cell can walk through, 
either going back up to a more permissive state (Fig. 3-B) either move directly to a different 
cell fate (Fig. 3-C). 
 
 
Figure 2: The Weddington Epigenetic landscape. Adapted by Weddington 1957. 
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Figure 3: Schematic illustration of Weddington's epigenetic landscape model. A | In normal 
development, a pluripotent cell (which is represented by a marble at the top of the hill) 'rolls' down 
a landscape that segregates into different groves on the slope. Depending on in which groove the 
marble falls, the cell acquires a distinct tissue-specific fate. B | A differentiated cell, which is 
reprogrammed to pluripotency, is symbolized by a marble rolling from the bottom of the hill back 
to the top. From there, it can be re-differentiated into another somatic cell type. C | During direct 
conversion, a tissue-specific cell directly converts into a related tissue-specific cell (symbolized by a 
marble 'jumping' over a low hill) or into a cell type of another germ layer (depicted by a marble 
jumping over a higher hill). The schematics are based on the original model presented in Fig. 2. 
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Adult Stem cells  
 
Adult stem cells do not show a stemness potential comparable to an embryonic stem cell, 
but the possibility of autologous treatments and the advances in the reprogramming 
technology ensure that adult stem cells continue to have a privileged position in the 
research. In addition we must not forget that the use of adult stem cells for medical 
purposes allow the avoidance of several ethical issues that rise with the usage of embryonic 
stem cells. Moreover the chance to get an autologous treatment by the use of self-adult 
stem cells offer a ploy to avoid rejection of the transplanted material by the immune system 
[Graph versus host disease]. In addition, in contrast to embryonic stem cells adult stem cells 
are believed not form teratomas when transplanted. Adult stem cells are supposed to 
reside in all the tissues and organs of the body, in which they participate in the physiological 
control of the normal tissue turnover. Examples of adult stem cells are multiple: satellite 
cells constitute a population of adult stem cells for the muscle regeneration (Chargé SB, 
Cellular and molecular regulation of muscle regeneration., 2004), neural stem cells are 
found in the nervous system (R., 1997), or epithelial stem cells in epidermis and intestinal 
crypts (Slack, 2000), and much more. Despite the different location and origin all these cell 
populations appear to be quiescent in a physiological state, once activated they are able to 
generate a progenitor cell that will go under cell lineage decisions and progressively 
differentiate into the designed cell type to keep the normal tissue homeostasis. Overall 
further investigations on adult stem cells are still required to evaluate their real potential 
for cell transplantation purposes. Although, as already discussed, the progress regarding 
the reprogramming technology does not require the use of stem cells as a starting point, 
adult stem cells seem to show a privileged epigenetic signature, if compared with other cell 
types, which eventually can make them easy to reprogram in vitro. 
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Mesenchymal stromal cells (MSCs)  
 
In the variety of several types of adult stem cells mesenchymal stromal cells or 
mesenchymal stem cells (MSCs) are considered one of the best eligible source for cell 
therapy. The first description of MSCs was in 1924, when a Russian-born morphologist 
Alexander A. Maximow (Maximow, 1927) used extensive histological findings to identify a 
singular type of precursor cell within mesenchyme that develops into different types of 
blood cells. Afterwards MSCs were identified as a subpopulation of bone marrow cells with 
osteogenic potential and subsequently were confirmed to contain clonal, plastic adherent 
bone marrow derived non-hematopoietic stem cells (Friedenstein AJ P. K., 1968). While the 
terms Mesenchymal Stem Cell and Marrow Stromal Cell have been used interchangeably, 
neither term is sufficient. The mesenchyme in fact is an embryonic connective tissue that 
derives from the mesoderm that differentiates into hematopoietic and connective tissue, 
whereas MSCs do not differentiate into hematopoietic cells (PORCELLINI, 2009). On the 
other hand stromal cells are connective tissue cells that form the supportive structure in 
which the functional cells of the tissue reside. While this is an accurate description for one 
function of MSCs, the term fails to convey the relatively recently discovered roles of MSCs 
in the repair of tissue (Valero MC, 2012). Subsequent experimentation revealed the 
plasticity of marrow cells and how their fate could be determined by environmental cues. 
For instance culturing marrow stromal cells in the presence of osteogenic stimuli such as 
ascorbic acid, inorganic phosphate, and dexamethasone could promote their differentiation 
into osteoblasts. In contrast, the addition of transforming growth factor-beta (TGF-b) could 
induce chondrogenic markers (Yang Z, 2009). Currently, the most excepted term is 
Mesenchymal Stromal Cells and is therefore used throughout this thesis (Horwitz EM & 
Therapy., 2005). 
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Sources of Mesenchymal stromal cells (MSCs) 
 
Although first described in the bone marrow, later studies demonstrated that MSCs exist in 
almost any tissues such as, but not limited to, adipose tissue (Kisiel AH, 2011), umbilical 
cord blood (Ong WK, 2013)muscle tissue (Jankowski RJ, 2002), neuronal tissue (Gage FH, 
1995), and more recently also liver (Pan Q, 2011) (da Silva Meirelles L, 2006). The youngest 
most primitive MSCs can be obtained from the umbilical cord tissue, namely Wharton's jelly 
and the umbilical cord blood. However the MSCs are found in much higher concentration 
in the Wharton’s jelly compared to the umbilical cord blood, which is a rich source of 
hematopoietic stem cells. The umbilical cord is easily obtained after the birth of the 
newborn, which is normally thrown away and poses no risk for collection. The umbilical cord 
MSCs show more primitive properties than other adult MSCs obtained later in life, which 
might make them a useful source of MSCs for clinical applications (Baertschiger RM, 2009).  
Still now, the best well-characterized source for adult stem cells is the bone marrow. Adult 
bone marrow contain a heterogeneous population of cells (Yo Mabuchi, 2013), including, 
hematopoietic stem cells (HSC), macrophages, erythrocytes, fibroblast, adipocytes, 
endothelial cells and a subset of non-hematopoietic stem cells with multilineage potential: 
the so called mesenchymal stromal cells. These MSCs resident in the bone marrow (BMSCs) 
are supposed to be fundamental for the correct maintenance and survival of HSCs. The role 
of the BMSCs seems to act as a suppressor of the immunogenic stimuli in the bone marrow 
avoiding the mobilization of HSCs from the niche. Current models envisage two distinct 
areas in the bone marrow that control HSCs homeostasis: the endosteal niche and the (peri-
) vascular niche (Krause DS, 2013) (Fig. 4). The endosteal niche mainly mediates HSC 
retention, maintenance and quiescence, whereas activated self-renewing HSCs are mainly 
found in a (peri-) vascular location. Both regions are strongly interconnected, and the 
emigration of HSCs from the bone marrow requires transit in and out of the (peri-) vascular 
niche (Le Blanc K, 2012). Moreover BMSCs are supposed to contribute in vivo in the 
formation of osteocytes and chondrocytes, it follows that BMSC are important for the 
maintenance of the niche itself, for example osteoblasts support HSCs, whereas adipocytes 
are negative regulators of HSCs.  
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Figure 4: Hematopoietic stem cell niches. On the left the Endosteal niche and on the right the 
perivascular niche (Adapted by (Ehninger A, The bone marrow stem cell niche grows up: 
mesenchymal stem cells and macrophages move in., 2011)). 
 
Another abundant and accessible source of stem cells is the adipose tissue. These cells, 
called adipose-derived stromal cells (ASCs), are fibroblast-like cells capable of multipotential 
differentiation which have been found in different species ( (Vieira NM, Isolation, 
characterization, and differentiation potential of canine adipose-derived stem cells., 2010) 
– (Rozemuller H, 2010)). MSC cultures from adipose tissue are considered heterogeneous 
because attempts to characterize an ASCs-specific cell surface marker have shown that cells 
derived from distinct marker sets can have MSC potential (Gomillion CT, 2006). In man, ASCs 
for autologous transplantation are usually isolated (Zuk PA, 2001) relatively quickly from 
adipose tissue by collagenase digestion after liposuction cosmetic surgery. Successful 
transplantation of canine adipose-derived stem cells (cASCs) in dogs was reported by Li et 
al. (Li H, 2007) and Black et al. (Black LL, 2007). The first group reported the beneficial 
effects of using ASCs – bone morphogenetic protein 2 (BMP2) enhanced – in the treatment 
of canine ulnar defects, and the second for the treatment of chronic osteoarthritis of the 
hip.  
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Recently van der Laan and colleagues (Pan Q, 2011) have shown the presence and the 
possibility to isolate a population of liver-derived mesenchymal stromal cells (LMSCs). In 
particular these cells were isolated from liver graft preservation fluid (perfusates) in which 
the liver is kept until a transplantation, these cells were compared on a genome-wide gene 
expression analysis showing high similarities with human BMSCs. LMSCs derived from man 
completely resemble the criteria for the definition of MSC, in addition to the three lineage 
differentiation the authors showed the possibility to differentiate LMSCs towards a hepatic 
fate, this extend the amount of possibilities in which we can utilize LMSCs. Moreover these 
cells appear to have a high modulation effect on the T-cell proliferation (See further: The 
immune modulatory activity of MSCs). From this prospective MSCs appear once more an 
ideal population for clinical purposes confirming the suitability in both allogenic and 
autologous treatments. Indeed one of the aims of this thesis is the comparison between 
canine and human LMSCs. 
 
 
 
Figure 5: Mesenchymal stromal cells. The plastic-adherent cellular fraction of many organs contains 
stromal progenitor cells that can give rise to colonies of fibroblastic morphology. When cultured 
under the appropriate conditions, colonies derived from single cells (colony-forming unit-
fibroblasts-CFU-Fs) can be isolated and expanded after multiple passages in vitro without losing their 
multipotent mesenchymal phenotype. (Picture adapted by (Le Blanc K, 2012)). 
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Definition and characterization criteria for MSCs 
 
Due to the various ways and locations from which these cells can be isolated and cultured, 
and the absence of a complete equivalency of these population, a certain level of confusion 
arose in defining MSCs. For this reason the International Society for Cell Therapy (ISCT) 
proposed a new terminology and criteria to define the MSC population. According to these 
widely adopted proposals, the cells were more appropriately considered mesenchymal 
stromal cells meaning that not all of them were stem cells. Moreover a minimum criteria 
for defining these cells has been proposed (Horwitz EM & Therapy., 2005) (Fig. 6): first these 
cells must adhere to culture plastic when maintained in standard culture conditions, second 
they must express markers such as CD105, CD73 and CD90 and lack expression of CD45, 
CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR (CD74) surface molecules; third MSCs 
must be able to differentiate into osteocytes, adipocytes, and chondrocytes in vitro. 
Interestingly, no evidence of asymmetric cell division, which is considered a property of self-
renewing cells in some setting has yet been proven for MSCs (Wu PS, 2008). It is important 
to note that our knowledge of MSCs is almost entirely based on the characterization of 
cultured cells, therefore our definition of MSCs is an “operational" one. An important 
question that raised from these considerations is the in vivo function and derivation of these 
cells. Even now the in vivo function is a subject of debate since these cells only constitute 
an in vitro phenomenon.  
 
Figure 6: Minimal criteria to define MSC. Table adapted by (Horwitz EM & Therapy., 2005). 
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In vivo function of MSCs 
 
Over the years it has become progressively accepted that MSCs could be the basis for a 
natural system of tissue repair (Prockop, 2007). It is believed that the in vivo function of 
MSCs is to contribute in tissue regeneration by either a direct repopulation effect or by 
secreting molecules that are capable to stimulate the normal regeneration of the tissue. 
Several studies have demonstrated the large potential of adult MSCs to differentiate into 
several differentiated cells (Fig. 7). Curiously in the majority of the studies on the 
therapeutic efficacy does not correlate with the efficiency of engraftment, suggesting that 
the major repair is achieved through an indirect activity (paracrine activity). This indirect 
effect is achieved through the secretion of molecules that alter the tissue 
microenvironment and to a lesser extent through transdifferentiation of MSCs into the 
appropriate cell phenotype (Phinney DG, 2007). In addition the secreting activity of MSC 
has evoked an increased interest in recent years due mostly to the immune modulatory 
properties that these cells shown. In addition, since MSCs are in an immune-privileged (See 
further) state they could prove to be valuable in allogeneic cell transplantation approaches. 
Although their possible role in tissue homeostasis and repair, the developmental origin of 
MSC is still a matter of debate. It is widely believed that MSCs have a mesoderm derivation, 
however Takashima et Al. (Takashima Y, 2007) showed that during embryonic development 
of the trunk it is possible to isolate a population of MSC-like cells that express specific neuro-
epithelium markers. A link between this population the cells of the neural crest seems 
possible, also taking into account that it has been demonstrated that cells of the neural 
crest migrate into the bone marrow (Nagoshi N, 2008), however the potential link between 
the cells of Takashima and MSCs has not been proven. Caplan et al. on the other hand 
proposed that MSCs can be thought as a pericytes derived cell population or that their niche 
resides in close proximity to (Caplan AI, 2011); this, with the idea that endothelial 
progenitors and mural cells may share the same vascular progenitor (Yamashita, 2000), 
would suggest that MSCs, HSCs and endothelium progenitor cells (EPCs) could arise from a 
common progenitor. 
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Figure 7: Mesenchymal stromal cell differentiation. MSCs can be cultured in vitro to generate a 
variety of differentiated cells and demonstrate their multi-potent capacity and differentiation 
plasticity. The end-stage cell type is dependent on the culture conditions, media, and supplements. 
Adapted by (Bonfield TL, 2010).  
13 
 
The immune-modulatory activity of MSCs 
 
The release of a multiplicity of bioactive molecules by MSCs are able to modulate several 
different types of cells including cells from the immune system. The immune-modulatory 
activity of the MSC cell population is one of the main features that place these cells as a 
major area of interest in the biomedical sciences. Recently some of the immune response 
pathways that are potentially modulated by the MSCs have been elucidated and they seem 
to relay on both direct contact as well as paracrine modulation. It is believed that the in vivo 
reflection of this immune modulatory effect stems from the fact that MSCs in the bone 
marrow (stromal cells) might serve to protect the sensitive hematopoietic stem cell 
population from being mobilized from the immune system (Lepperdinger, 2011). 
Lymphocytes and natural killer cells are potential sources of pro-inflammatory cytokines, 
MSC interact with T-cells and many other immune cells thereby promoting dominant 
modulatory processes (Fig. 8). The effects on CD4+ and CD8+ T-cells are best characterized 
(Dazzi F, 2011). Inhibition of T-cell proliferation by MSCs, for example, depends on the arrest 
of T-cells in the G0/G1 phase (Krampera M, HB-EGF/HER-1 signaling in bone marrow 
mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage 
differentiation., 2005). MSCs in fact do not promote T-cell apoptosis, but instead they 
support their survival in a state of quiescence. This mechanism has shown to induce a shift 
from a pro-inflammatory state of T-cells, that in this fashion produce IFNγ that stimulates 
both the innate and the adaptive immunity (i.e. it is able to trigger macrophages activation), 
to an anti-inflammatory state in which T-cells produce Interleukin 4 (IL-4) that lead to a 
decrease of the inflammatory response. An example of this activity is the expression of 
Prostaglandin E2 (PGE2), a molecule with immunosuppressive potential that is selectively 
produced by MSCs. It acts in synergy with indoleamine-2,3-dioxygenase (IDO), and MSC-
derived PGE2 is capable to reverse an inflammatory into an anti-inflammatory environment, 
altering the cytokine secretion profile of dendritic and T-cell subsets (Trento C, 2010). 
Moreover IDO induces the depletion of tryptophan from the local environment, which is an 
essential amino acid for lymphocytes proliferation (Uccelli A, 2008). Owing to the reversible 
nature of this inhibition, responding cells are not triggered to undergo apoptosis; it appears 
likely that MSC to all intents and purposes protect from apoptosis, which is in concordance 
with the notion that the actual duty of MSC is to support tissue repair.  
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These modulatory activities of MSCs appear to be important also in the liver regeneration 
process by secreting factors that promote hepatocytes proliferation; interestingly it has 
been shown that treatment with a concentrate of conditioned media of liver MSCs in vitro 
promote in vivo liver regeneration (Fouraschen SM, Secreted factors of human liver-derived 
mesenchymal stem cells promote liver regeneration early after partial hepatectomy., 2012). 
  
 
 
Figure 8: The anti-inflammatory effect of MSCs offer by secreting growth factors and cytokines as 
well as using cell-cell interactions. Pathway 2-4 and 6 show how MSCs affect the innate immune 
response whereas pathways 1 and 5 show MSCs effect on the adaptive immune response (Aggarwal 
S, 2005).  
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Therapeutic potential of MSCs 
 
Although clinical interest in cultured mesenchymal stromal cells initially focused on the 
potential of their stem cell-like properties for tissue regeneration and repair, the discovery 
of their paracrine properties markedly increased the range of therapeutic applications for 
which they are currently studied. Systemic infusion of mesenchymal stromal cells has 
proved beneficial in different preclinical models of acute lung injury, myocardial infarction, 
diabetes, multiple sclerosis, as well as renal and hepatic failure (Uccelli A, 2008). Although 
the mechanisms underlying the therapeutic effects of MSCs in these disease models are not 
well characterized, they are thought to partially depend on the release of a combination of 
multiple bioactive molecules with anti-inflammatory, anti-proliferative, anti-apoptotic and 
angiogenic properties. The current hypothesis is that paracrine factors secreted by 
mesenchymal stromal cells provide protective micro environmental cues and promote 
repair by local tissue-resident progenitor populations, thereby explaining the detection of 
favorable effects even in the absence of prolonged mesenchymal stromal cell engraftment 
in sites of injury as already discussed previously. These findings have prompted clinical 
studies on the therapeutic potential of mesenchymal stromal cells. For instance, the 
osteogenic properties of mesenchymal stromal cells have been used to treat children with 
osteogenesis imperfecta and have shown promising outcomes (Horwitz EM G. P., 2002). On 
the basis of their immunoregulatory and tissue protective properties, mesenchymal stromal 
cells are also being tested for the treatment and prevention of graft-versus-host diseases. 
Nevertheless, in most cases, these studies are preliminary, and treatment efficacy has not 
been conclusively established. Some of the major questions that still need to be resolved 
concern the standardization of protocols for the isolation of mesenchymal stromal cells and 
their expansion in vitro, the safety of such cell-based therapies and the homing and 
engraftment of mesenchymal stromal cells to their target tissues. In addition, the lack of a 
large animal model hampers the translation of fundamental mouse studies to a clinical 
application in human diseases. 
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The Liver 
 
Before we can discuss the therapeutic potential of MSCs for the treatment of liver diseases. 
We will now focus on the liver morphology, function, regeneration, and pathobiology. Liver 
development is not included in this segment but is described in detail by Aaron M. Zorn, et 
al. (StemBook Chapter - 15 Jan 2009). 
 
The liver is the largest internal organ and it provides many essential metabolic, exocrine and 
endocrine functions, these include production of bile, metabolism of dietary compounds, 
detoxification, regulation of glucose levels through glycogen storage, and control of blood 
homeostasis by secretion of clotting factors and serum proteins such as albumin. The liver 
lies in the abdominal cavity, in contact with diaphragm.  Its mass is divided into several lobes 
(Fig. 9), the number and size of which vary among species. In most mammals, a greenish sac 
- the gall bladder - is seen attached to the liver sharing a common bile duct, which delivers 
bile from the liver and gall bladder into the duodenum. Hepatocytes are the principal cell 
type in the liver and these along with biliary epithelial cells are derived from the embryonic 
endoderm. 
 
 
 
Figure 9: Representation of the lobes subdivision of the liver in man, looking from different 
orientations (Adapted from (Varotti G, 2004)). 
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Understanding function and dysfunction of the liver, more than most other organs, depends 
on understanding its structure, focusing mainly on its vascular system, the organization of a 
biliary tree in a specific three-dimensional arrangement. 
One of the unique characteristics of the liver is undoubtedly its hepatic vascular system (Fig. 
10): almost all the blood is venous blood returning from the small intestine, stomach, 
pancreas and spleen that converges into the portal vein. One consequence of this is that the 
liver gets "a sip” of everything absorbed in the small intestine, which is where virtually all 
nutrients are absorbed. The remaining blood fraction is arterial blood coming from the 
hepatic artery. These two sources of blood empty together and mix as they merge in the 
sinusoids. Sinusoids are fenestrated vessels that circumvent the hepatocytes. As blood flows 
through the sinusoids, a considerable amount of plasma is filtered into the space between 
endothelium and hepatocytes (so called: "space of Disse"), providing a major fraction of the 
body's lymph. Once the blood has passed through the sinusoids, it empties into the central 
vein of each lobule, those become hepatic veins that convey in the vena cava. 
 
 
Figure 10: Representation of the liver vascular system (adapted by 
https://courses.stu.qmul.ac.uk/smd/kb/microanatomy/d/alimentary/) 
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Adjacent to the vascular system  runs the biliary tree, the biliary system consist of a series 
of channels and ducts that conveys bile - a secretory and excretory product of hepatocytes - 
from the liver into the lumen of the small intestine. Hepatocytes are polarized cells with 
their apical surfaces facing and surrounding the sinusoids. The basal faces of neighboring 
hepatocytes are welded together by junctional complexes to form the canaliculi, the first 
channel in the biliary system. A bile canaliculus is not considered a duct, but rather, the 
dilated intercellular space between adjacent hepatocytes. Hepatocytes secrete bile into the 
canaliculi, and those secretions flow parallel to the sinusoids, but in the opposite direction 
that blood flows. At the ends of the canaliculi, bile flows into bile ducts, which are true ducts 
lined with epithelial cells. Bile ducts thus begin in very close proximity to the terminal 
branches of the portal vein and hepatic artery, and this group of structures is an easily 
recognized and important landmark seen in histologic sections of liver - the grouping of bile 
duct, hepatic arteriole and portal venule is called a portal triad. The biliary tree convey all 
together into larger ducts to end into the large common bile duct which dumps bile into the 
duodenum. A sphincter known as the sphincter of Oddi is present around the common bile 
duct as it enters the intestine. Adhering to the liver common bile duct there is the gall 
bladder. This is a sac-like structure which has a duct, the cystic duct that leads directly into 
the common bile duct. During periods of time when bile is not flowing into the intestine, it 
is diverted into the gall bladder, where it is dehydrated and stored until needed. 
 
As briefly discussed above the topographic organization has an important role in 
accomplishing its function. To maintain and protect this 3D organization the liver is covered 
with a connective tissue that pervade all of its mass. This connective tissue tree provides a 
scaffolding support for the entire organ, in addiction the layers of connective tissue divide 
the parenchyma of the liver into very small units called lobules. The hepatic lobule is the 
structural unit of the liver. It consists of a central vein, at the vertex of the lobule are regularly 
distributed portal triads, containing a bile duct and a terminal branch of the hepatic artery 
and portal vein. The portal triad is surrounded by hepatocytes arranged in single cell sheets 
known as hepatic plates (Fig. 11).  
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Figure 11: Representation of the topological distribution of hepatocytes plates. All the cells are 
located on a single cell layer, in the center the central vein which receive fluids from all the lobule 
thanks to the sinusoid network. 
 
 
 
Figure 12: Three-dimensional structure of a liver lobule. The liver receives 75% of its blood supply 
from the portal vein and the rest from the hepatic artery. The portal veins and hepatic arteries 
terminate in the intrahepatic portal tracts, which contain bile ducts that transport bile from the 
canaliculus through the extrahepatic biliary system to the gut. The terminal portal veins give rise to 
septal branches that drain blood into the sinusoids that make up the distributing system, which 
takes blood through the acinus to the central vein. The hepatic artery terminates in axial branches 
that run parallel to the portal vein and terminate in the sinusoids. The sinusoids are lined by 
morphologically and phenotypically unique endothelial cells (see inset) that are characterized by 
the absence of tight junctions, the absence of a recognizable basement membrane and the presence 
of open fenestrae that are organized into sieve plates. The sinusoidal endothelium is interspersed 
with macrophages that are known as Kupffer cells and overlies the space of Disse, which contains 
extracellular matrix proteins and fibroblasts that are known as hepatic stellate cells. Dendritic cells 
from the parenchyma exit the liver through the space of Disse (Adams DH, 2006).   
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Regeneration of the liver 
 
The liver is a highly regenerative organ with a remarkable ability to restore its original mass 
following parenchymal cell loss (Fausto N R. K., 2005). After parenchymal loss a process of 
general hyperplasia occurs which aim is to reconstitute the loss of mass in order to 
reestablish the normal liver function. However this ability is impaired in numerous diseases 
such as advanced acute or chronic hepatitis in which liver transplantation is still the only 
curative treatment. Nowadays 170 million patients world-wide are estimated to suffer by a 
form of chronic liver disease, of these about one third can be expected to develop significant 
fibrosis and eventually cirrhosis (Sokal EM, 2003); for this reason understanding the 
molecular insight of the liver regeneration constitute an important challenge for the 
regenerative medicine field. One of the first questions to be asked is which cell types 
participate in the process and how they modulate regeneration. Growth of the adult liver is 
supported by two main cell populations: hepatocytes and progenitor cells, the latter also 
known as oval cells in rodents. The hepatocytes, which are normally quiescent, constitute 
the first line of response to injury or resection. Progenitor cells function as a reserve 
compartment (Fausto N R. K., 2005) in the situation where hepatocytes proliferation is 
inhibited (Oertel M, 2008). The progenitor cells are supposed to originate in the canals of 
Hering (Theise ND, 1999). Progenitor cells are activated in the majority of liver diseases 
(Roskams TA, 2003), but there activation is considered too little or too late in the majority 
of the cases.  
Regeneration by hepatocytes has been studied in great detail, several studies have 
demonstrated that after partial hepatectomy 95% of the hepatocytes enter the cell cycle 
again and undergo at least one division. Although the priming process shows similarities 
along the species, the time-course of the process differs, reflecting differences in the cell 
cycle spawn. To note, the percentage of hepatocytes that divide during liver regeneration 
drops considerably in old animals compare to young (Butcher, 1963). Experiments led to 
investigate these differences in the replication ratio of hepatocytes among species showing 
that there are differences among species. Interestingly Weglarz and Sandgren (Sandgren, 
2000) compared the proliferation ratio of rat and mouse hepatocytes in a partial 
hepatectomy system demonstrating that indeed they share common pathways but they 
react to them in a species specific manner. The concept by which liver regeneration occurs 
among species trough the same molecular pathways has been shown also specifically for 
the dog (Spee B A. B., 2006) (Fig.13). 
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Figure 13: Liver cells types and their organization. Progenitor cells, in violet, under opportune 
mitogenic stimuli can trigger the so call ductural reaction by which progenitors cells might go either 
through a cholagiocyte lineage or a hepatocyte lineage. Adapted by Spee et al., 2006. 
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The dog as a model 
 
Although the use of murine models in the field of hepatology has increased our knowledge 
of liver regeneration considerably, several aspects of regenerative medicine can only be 
studied in a large animal model. When concerning cell therapy, the life span and size of 
murine models does not allow enduring longitudinal studies for safety and efficacy. One 
large animal model that is gaining increased intention is the dog. For more than a century, 
dogs have been successfully developed as an experimental model system. As a model 
system, dogs provide unique advantages due to their close relationship with humans. 
Because dogs live with humans, they are exposed to the same environmental factors, and 
adhere to similar lifestyle and diet. As a result, the rise in lifestyle diseases such as obesity, 
diabetes and liver disease in the human population is accompanied by a similar rise in these 
pathologies in dogs. In addition, specific breeds are prone to genetic disorders that carefully 
recapitulate the human disease. Yet unlike human genetic disorders, due to selective 
inbreeding, the genetic variability within breeds is limited, clearly facilitating genetic studies 
on complex inherited diseases. This has prompted various groups to initiate genetic linkage 
analyses in specific dog breeds ( (Parker HG K. L., 2004); (Xie, 2005); (Khanna C, 2006); 
(Karlsson EK, 2007)) and it is apparent that the canine model system provides unique 
insights into human biology and disease (Parker HG S. A., 2010). 
 
Taken together, dogs are an extremely informative model species to bridge fundamental 
mouse models and human clinical practice. For various reasons, the translation from mouse 
models into human clinical practice has been little successful. This is particularly true for 
liver diseases which for the dog are highly comparable to man on a pathophysiological level 
(Spee et al, 2006 & 2007). For example, Dogs with a Mendelian inherited copper storage 
defect due to a mutation in the COMMD1 gene (van De Sluis B, 2002) develop chronic 
hepatitis highly similar to Wilsons disease in man (Favier RP, 2011). These similarities are 
not just based on histology, but more importantly the signal cascades that are affected are 
similar in both species. Isolation and regulation of human and canine adult stem cells 
confirmed the strong similarities in tissue homeostasis and pathogenesis between these 
species ( (Schotanus BA, 2009); (Arends B, 2009)). 
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Working hypothesis 
 
1. Mesenchymal stromal cells (MSCs) are present in the canine liver. 
2. Both the perfusion and the enzymatic digestion of liver can be used for the isolation 
of LMSCs. 
3. DMEM media shows superior level of cell growth compared to αMEM. 
4. Addition of growth factor to the culture condition has a positive effect on the 
proliferation of LMSCs. 
5. LMSCs and BMSCs show overall comparable results on different levels of analysis: 
cell growth, gene expression profiling, FACS analysis, and differentiation potential.  
6. LMSCs show indication of an activated prostaglandin pathway. 
 
Aim of the thesis 
 
The lack of common standards and precise definition of initial cell preparation remain a 
major obstacle in research on MSCs and their application; the aim of this thesis is to 
compare the characterization of LMSCs and BMSCs collected in the canine model. The 
possibility to compare different types of MSCs isolated from the same donor offer a 
privileged experimental setting for these purposes. The characterization of these cell 
populations based on the proposed terminology and criteria according to the International 
Society for Cell Therapy (ISCT) including gene-expression profiling in conjunction with the 
FACS analysis will allow the exploitation of quested differences between the MSC types. To 
conclude this research will be the basis on which clinically applied mesenchymal stromal 
cells can become a reality within the veterinary field. This will, in turn, provide some of the 
necessary information to apply these cells in human clinics. 
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Material and methods 
 
Cells sampling 
All canine MSCs were isolated from dogs that were euthanized for other unrelated 
experiments approved by the Ethics Committee on Animal Experimentation of Utrecht 
University. In particular all the individuals were either Labrador, 19 weeks old, or Beagle, 1 
or 2 to 5 years old. 
 
Bone marrow derived- stromal cells (BMSCs) 
MSCs were obtained from the diaphysis of the homerus and/or femur. To collect the bone 
marrow, each diaphysis was flushed and curetted with heparinized α-MEM (Invitrogen 
22561) supplemented with 10% Fetal Bovine Serum Gold (FCS, PAA Laboratories A15-151) 
and 1% penicillin/streptomycin (PAA Laboratories P11-010). The aspirates were seeded at 
a density of 100-150x106 cells per T175 culture flask (Cell star). After 24 hours, non-
adherent cells and cell debris were washed out with 2% Hanks Balanced Salt Solution (HBSS) 
+ 2% FCS. The BMSCs were further expanded in α-MEM + 10% FCS + 1% 
penicillamine/streptomycin (p/s) + 0.05% Fungizone (Invitrogen) + 0.1mM ascorbic acid-2-
phosphate (Sigma A8960) + 10-9M dexamethasone (DMSO, Sigma D1756) + FGF 1 ng/mL 
(AbD serotec). Cells were cultured at 37°C under humidified conditions in air containing 5% 
carbon dioxide. MSCs appeared rounded at first and after approximately 3-4 days they 
appeared spindle like. On average, they reached 80% confluency within 7 days and were 
then cryopreserved in α-MEM + 10% DMSO + 10% FCS at P0. After thawing, cells were 
seeded at 1x106 per T175 and expanded up to P2, followed by cryopreservation until further 
analysis (gene expression profiling and FACS analysis).  
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Liver mesenchymal stromal cells (LMSCs) 
Two main approaches have been tested for the isolation of LMSCs: an enzymatic digestion 
from a chopped sample and a perfusion with HBSS of the whole lobe trough the blood 
vessels. 
 
Enzymatic digestion 
Enzymatic digestion of the wedge liver biopsies has been performed as described in 
supplemental annexes: protocol 1. In short, the liver was excised aseptically from the 
cadaver and a wedge biopsy was placed in cold HBSS. Immediately after the surgical 
sampling the wedge biopsy was minced and frozen in multiple cryovials, on average 1.9g of 
tissue each, in 50% DMEM + 40% FCS + 10% DMSO. Several enzymes have been tested for 
tissue digestion (Table 1): Liberase (0.23 Wunsch unit/ml, Roche Diagnostic), Dispase (0.4 
U/mL, Gibco), Collagenase Type II (50 U/mL, Worthington) and a combination of Dispase 
(0.4 U/mL, Gibco) and Collagenase Type II (60 U/mL, Worthington). After digestion two 
fractions of cells were collected by low speed centrifugation (50g, 10 min). The cell pellet 
obtained after the first centrifugation step is considered the parenchymal fraction. The cell 
pellet after the second centrifugation step of the supernatant (200g 10 min) is considered 
the non-parenchymal fraction. Liver MSCs have been found in both of the fractions 
although a larger amount have been found in the parenchymal fraction, for this reason the 
parenchymal fraction has been selected as the preferred starting point. Before this decision 
a gene expression profile analysis had been performed to ensure the absence of putative 
differences between the fractions derivation (data not shown). 
 
Table 1: Enzymes tested for the digestion of liver tissues and relatives enzymatic units used. 
 
 
 
 
Enzyme Enzymatic unit 
Collagenase T2 50 U/mL 
Liberase 0.23 WU/mL (Wunsch units) 
Dispase 0.4 U/mL 
CollagenaseT2 + Dispase 50 U/mL + 0.4 U/mL 
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Liver Perfusion 
For the perfusion of a liver lobe the liver was removed aseptically from the cadaver and the 
left lateral lobe of the liver was removed. Cold Hanks Balanced Salt Solution (HBSS, Gibco) 
was flushed through the liver with a large syringe (50 mL Falcon syringe), several fractions 
of 50 mL perfusate were collected and analyzed. Because of the large amount of red blood 
cells in the perfused fraction a centrifugation (400 g, 30 min) with Ficoll (1:1-10mL Ficoll: 
10mL media- , FICOLL-PLAQUE™ plus, cat. 07957 StemCell technology) gradient has been 
performed, this allowed us to isolate the mononuclear cells only; in this fashion cells were 
able to attach to the plate with higher efficiency. 
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Cell culture 
Cells obtained from either the parenchymal fraction or the mononuclear fraction from the 
perfusion were seeded in a 6 well plate format. After 24h non-adherent cells and cell debris 
were washed out with pre-warmed HBSS and standard culture conditions were added. Cells 
were cultured under different conditions to investigate the optimal culture conditions for 
LMSCs. The most common expansion media used for MSCs cultures is DMEM with the 
addition of fetal calf serum (FCS), in addition to this setting we also tested the αMEM and 
the use of additives such as basic Fibroblast Growth Factot (bFGF/FGF2) and ascorbic acid 
(AsAp – also known as vitamin C) in which canine BMSCs are cultured (Collaboration with 
Dr. MA Tryfonidou). Cells were washed twice a week and passed using trypsin for 5 min at 
37oC. For each passage cells were seeded in 6 well plates at a density of 6.25x103 cells/cm2 
(3.6x105 cells/plate). 
 
Viability assay 
To evaluate viability of LMSCs in different culture conditions, in particular DMEM + 10% FCS 
+ p/s or α-MEM + 10% FCS + 1% p/s + bFGF + AsAp, a 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma) assay was performed in 6 replicates per 
condition as previously described (Berridge MV, 2005). Cells were seeded at a density of 
9x102cells/cm2 in a 96well plate format and treated for 48 hours. Filtered MTT was added 
to the media (20µL to 100µL of media, 5mg/mL); after two hours of culturing cells were 
washed and 50 µL of DMSO was added to each well. After an incubation step on the orbital 
shaker the absorbance was measured with a plate reader at 595nm (DTX880 multimode 
detector with Anthos detection software, Beckman Coulter, Woerden, The Netherlands). 
Measurements were corrected for background absorbance present in negative controls 
wells (MTT/DMSO – no cells). 
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Proliferation assays 
To estimate the rate of cell proliferation of LMSCs in different culture conditions; DMEM + 
10% FCS + p/s and α-MEM + 10% FCS + 1% p/s with our without culture additives bFGF and 
AsAp, a 5-ethynyl-2’-deoxyuridine (EdU) incorporation assay was performed according to 
Salic et al.2008 (Salic A, 2008). In short, cells were seeded at a density of 9x102cells/cm2 in 
a 96 well/plate format, after 48 hours of culture EdU (10µM) was added to the media and 
incubated for 2 hours. At this point EdU will be incorporated in the DNA during the S-phase. 
Cells were than washed with HBSS, fixed in freshly prepared PFA 3.7% for 10 min at RT, 
washed and stored in sterile PBS at 4°C until a Cu(I) catalyzed EdU click-chemistry reaction 
was performed followed by a 5µM Alexa Fluor 488-azide step (Invitrogen, Breda, The 
Netherlands) and DAPI 1:1,000 counter stain (Invitrogen). The percentage of EdU positive 
cells in each well was measured relative to the total number of cells by automated read out 
on an ArrayScan™VTI (600 series), version 6.6.1.3-1.00x with an algorithm created 
appositely for LMSCs. 
 
Population doubling assay 
To establish the growth potential with a population doubling assay, LMSCs were seeded at 
a density of 6.25x103 cells/cm2 (in a 6 well plate format). BMSCs were seeded at a density 
of 5.714x103 cells/cm2 (in 175 cm2 culture dishes). Every third day cells were trypsinised 
counted and seeded again at the same seeding density. With the number of cells obtained 
at each passage a population doubling (PD) estimation has been calculated using the 
formula reported below (Hayflick L., 1973): 
 
PD= 
(Log(Nf)−Log(Ni))
Log2
 
 
In particular PD tally the number of divisions that the cells do at each passage (3 days), Nf 
correspond to the cell count at the third day and Ni is the initial seeding amount (3.6×105). 
To note some of the results on the PD of the cells will be shown using cumulative population 
doubling (cPDs), in this fashion at each passage number will correspond the total number 
of estimated divisions per well up to that passage (i.e. cPDP2=PDP1+ PDP2). 
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RNA sampling and analysis 
From each passage (P0-P4) a total RNA isolation was performed using the RNeasy Micro Kit 
(Qiagen, cat. No. 74004) according to the manufacturer’s instructions as well as on-column 
DNase treatment (0.1 U/µL, QIAGEN, Benelux BV, Venlo, The Netherlands). RNA quantity 
and quality was analyzed using NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, 
DE). After isolation cDNA was created with the iScript cDNA Synthesis Kit (BioRad, 
Veenendaal, the Netherlands) according to the manufacturer’s instructions. RNA input for 
each sample was set at 350ng/µL. All the primers tested (Table 2) were designed using 
Perlprimer v. 1.1.21 (http://perlprimer.sourceforge.net) and ordered from Eurogentec. A 
quality control and an investigation of putative 3D rearrangements have been done using 
the mFOLD web tool (http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form); once 
tested the amplicons have been sequenced with a Big Dye Terminator Cycle Sequencing 
reaction using the 3130xl Genetic Analyzer (Applied Biosystems Ref: 3130XL) and finally 
blasted using the Ensemble database (http://www.ensembl.org/index.html) to prove the 
target identity. 
qPCR analysis has been performed in a 10µL volume, 384wells plate format, as described in 
the protocol and run in the C1000 Touch™ Thermal Cycler (Biorad ref: C1000 Touch™). In 
short, a standard pool (S1S7) was prepared from 5µL of each cDNA samples diluted 50x 
following a 4-fold dilution series. Data were analyzed using the comparative cycle threshold 
method with normalization of the raw data to six reference genes: 5S ribosomal RNA (RPS5), 
19S ribosomal RNA (RPS19), 13S ribosomal protein L13 (RPL13), hypoxanthine 
phosphoribosyltransferase 1 (HPRT), Tyrosine 3-Monooxygenase/Tryptophan 5-
Monooxygenase Activation Protein, Zeta (YWAZ), and β-2-microglobulin (B2MG). 
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Table 2: List of primers designed for the gene expression profile analysis. 
Gene Sequence Accession number Amplicon Temp. 
CD105 CAT-CCT-TCA-CCA-CCA-AGA-G 
CAG-ATT-GCA-GAA-GGA-CGG 
ENSCAFG00000020106 139 60 
CD90 CAG-CAT-GAC-CCG-GGA-GAA-AAA-G 
TGG-TGG-TGA-AGC-CGG-ATA-AGT-AGA 
ENSCAFG00000029265 134 63.5 
CD166 AAG-CGT-CAT-AAA-CCA-AAC-AG 
TAT-AGC-AGA-GAC-ATT-CAA-GGA-G 
ENSCAFG00000009721 150 61 
CD29 GAT-GCC-TAC-AAC-TCC-CTT-TCC-TCA 
CAT-TTT-CCC-CTG-TTC-CAT-TCA-CC 
ENSCAFT00000006178 118 60 
CD73 CTC-CAA-CAC-ATT-CCT-TTA-CAC 
ACT-CAA-CCT-TCA-AAT-AGC-CT 
ENSCAFG00000002994 150 61 
CD44 CTT-CTG-CAG-ATC-CGA-ACA-CA 
GAG-TAG-AAG-CCG-TTG-GAT-GG 
ENSCAFG00000006889 147 60 
CD45 GAC-CAT-GGG-GTG-CCT-GAA-GAT 
CAC-AAT-GGG-GCC-ACT-GAA-GAA-G 
ENSCAFG00000011265 90 60 
CD235
a 
AAGCAGGTTTCATTTCCACAG 
TCCCTATTATCACTGGTTCAGAG 
ENSCAFG00000031944 152 60 
CD11b ACT-CAG-ACA-GGA-AGT-AGC-A 
CAG-CAT-AAC-CCA-AGT-AAG-CA 
ENSCAFG00000016881 210 61 
CD14 CCC-GGC-GCT-CAC-CAC-CTT-AGA-C 
CCT-GGA-GGG-CCG-GGA-ACT-TTT-G 
ENSCAFG00000005852 98 60 
CD19 CAA-GAC-CAA-CTC-TCC-CAG 
CCT-CAT-TCT-CGT-AAG-ACT-CAG 
ENSCAFG00000017303 111 60 
CD144 GAT-ATT-CCA-TCC-GCA-AGA-CC 
AAT-CCA-GTT-CTT-TAG-CCT-CCA 
ENSCAFG00000020413 137 61 
Ck18 TTG-CTA-CCT-ACC-GTC-GCC-TGT-TGG 
ATC-TTG-CGG-GTG-GTG-GTC-TTC-TGG 
ENSCAFG00000007154 109 63.5 
Ck19 GCC-CAG-CTG-AGC-GAT-GTG-C 
TGC-TCC-AGC-CGT-GAC-TTG-ATG-T 
ENSCAFT00000025270 86 63.5 
Alb TGT-TCC-TGG-GCA-CGT-TTT-TGT-A 
GGC-TTC-ATA-TTC-CTT-GGC-GAG-TCT 
ENSCAFT00000004843 92 63.5 
Onecut
1 
ACC-CTG-GAG-CAA-ACT-CAA-GTC 
CCT-TCC-CAT-GTT-CTT-GTT-CTT-TCC 
ENSCAFG00000015867 - 58 
Onecut
2 
TGG-AGT-AAA-CTC-AAA-TCT-GGC 
CTG-TCT-TTG-TTT-GGT-TCT-TGC 
ENSCAFG00000000127 - 58 
CD255 GGA-AGA-GGC-CAA-AAT-CAA-CA 
ACC-AGC-AAG-TCC-AGC-TTC-AG 
ENSCAFG00000016618 150 63 
CD266 GAC-CTC-GAC-AAG-TGC-ATG-G 
CGA-GAA-GCC-AGA-AAG-CAG-TC 
ENSCAFG00000023134 165 63 
Nanog CAA-GCA-CCC-AAC-TCT-AGG 
GTC-CTG-AGT-AAG-CAG-ATC-C 
ENSCAFG00000031047 150 64.5 
Oct4 ACG-ATC-AAG-CAG-TGA-CTA-TTC-G 
GAG-GGA-CTG-AGG-AGT-AGA-GCG-T 
ENSCAFG00000000485 158 64.5 
Sox2 AAC-CCC-AAG-ATG-CAC-AAC-TC 
CGG-GGC-CGG-TAT-TTA-TAA-TC 
ENSCAFG00000011642 152 61 
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LGR5 AGT-CGA-TAC-CGG-AGA-AAG-CA 
GAG-GCA-CCG-TTC-AGA-GTC-A 
ENSCAFG00000000451 139 61 
LIN28 CCA-CCC-CAG-CCC-AAG-AA 
CAG-TGG-ACA-CGA-GGC-TAC-CA 
ENSCAFG00000012488 66 61 
CD133 CTG-GGG-CTG-CTC-TTT-GTG-AT 
AGG-CCC-CAT-TTT-TCT-TCT-GTC 
ENSCAFT00000044445 115 60.5 
CD74 CTG-CCC-ATT-CAA-AGC-CTG 
GTT-CTC-AAA-GAC-CTT-CCA-ATC-C 
ENSCAFG00000018101 197 64 
CD274 CGT-TCC-AGC-AAG-TGA-GAG 
CCA-CAT-CCA-TCA-TTC-TCC-C 
ENSCAFG00000002120 115 64 
PTGS1 GTT-CCT-GTT-CAA-CAC-CTC-C 
GTC-TAT-GTT-TCT-ACC-TCC-ACC 
ENSCAFG00000020263 105 61 
PTGS2 GTA-TGA-GCA-CAG-GAT-TTG-AC 
TGA-AGT-GGG-TAA-GTA-TGT-AGT-G 
ENSCAFG00000013762 149 60 
CD146 GGG-AAT-GCT-GAA-GGA-AGG 
CTT-GGT-GCT-GAG-GTT-CTG 
ENSCAFG00000012079 99 63 
RPS5 TCA-CTG-GTG-AGA-ACC-CCC-T 
CCT-GAT-TCA-CAC-GGC-GTA-G 
ENSCAFG00000002366 141 62 
RPS19 CCTTCCTCAAAAAGTCTGGG 
GTTCTCATCGTAGGGAGCAAG 
ENSCAFG00000001608 95 62 
RPL13 GCC-GGA-AGG-TTG-TAG-TCG-T 
GGA-GGA-AGG-CCA-GGT-AAT-TC 
ENSCAFG00000019840 87 62 
B2MG TCC-TCA-TCC-TCC-TCG-CT 
TTC-TCT-GCT-GGG-TGT-CG 
ENSCAFG00000013633 85 62 
HPRT AGC-TTG-CTG-GTG-AAA-AGG-AC 
TTA-TAG-TCA-AGG-GCA-TAT-CC 
ENSCAFG00000018870 104 58 
YWHA
Z 
CGA-AGT-TGC-TGC-TGG-TGA 
TTG-CAT-TTC-CTT-TTT-GCT-GA 
ENSCAFG00000000580 94 58 
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FACS sampling and analysis 
Cell fractions were collected during the passaging step specifically at P2 for cell sorting 
purposes; a minimum of 5x105 cells have been frozen in 50% αMEM, 40% FCS and 10% 
DMSO for FACS analysis. Fractions were seeded two to three days in advance before the 
analysis. For each antibody or control (Table 3) a titration experiment was conducted to 
estimate the best amount to use per reaction. Briefly, after trypsinization cells were 
counted and divided in nine fraction with a minimum of 50x103 to a maximum of 500x103 
per reaction. Cells were washed in Phosphate Buffered Saline (PBS, pH 7.4) and 
resuspended in 50µL of FACS buffer (PBS 1x, FCS 10% and Sodium azide 0.1% w/v). At this 
point cells were incubated with the antibody for 30 min on ice and then washed twice with 
FACS buffer, as to get rid of the non-bonded antibody. 
Prior to go to the FACS CANTO II (BD bioscences) for the analysis, 7-Amino-actinomycin D 
(7AAD, 0.25µg/test, BD Biosciences) was added in each tube, the 7AAD is a fluorescent 
marker for DNA which is used to detect dead cells as previously described from Lindén et 
al. (Lindén E, 1997). The system used for the analysis was a FACS Canto II (BD biosciences 
Cat: 338960), data were first collected with the FACS Diva software and the analysis has 
been performed with either FlowJo software (http://www.flowjo.com/) or Cytobank 
(https://www.cytobank.org/).  
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Table 3: List of antibodies included in the analysis. 
Target Host Reactivity Manufacture Cat.number 
CD105 Rabbit Dog-Pig Antibodies-online ABIN888668 
CD90 
 
Rat Dog eBioscence 12-5900-42 
CD29 Mouse Human-Cow-Dog BioLegend 303004 
CD166 Rabbit Human-Mouse-Rat-Cow-
Dog-Pig-Horse-Chicken 
Antibodies-online ABIN673954 
CD45 
 
Rat Dog LSBio LS-C127720 
Rat IgGk 
 
Rat - eBioscence 12-4031-82 
Rabbit 
IgGk 
Rabbit - Antibodies-online ABIN376422 
Mouse 
IgGk 
 
Mouse - BioLegend 400112 
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Differentiation assays and staining 
To test the real potential of LMSCs multiple differentiation assays were performed; cells 
were cultured at least one day in expansion media and then moved to specific 
differentiation condition as described in protocol (protocols listed in the annexes); for all 
the experiments condition media were change every three days for an estimate time of 
three weeks.  
 
Osteogenic differentiation: 
Cells were seeded at the density of 3000 cells/cm2 in a six well plate, in particular two well 
were left in basic culture media and used as a control. The culture conditions tested to 
stimuli the cells towards an osteogenic lineage were: DMEM HG + glutarmax + 10% FCS + 
1% p/s + AsAP 0.1 mM + Dexamethasone 0.1 µM (Sigma) + Glicerol-phosphate 2 mM 
(Sigma). After three weeks of culture in condition media cells were stained for 20 min with 
1,2-dihydroxyanthraquinone or Alizarine Red (333ng/mL) at a pH of 5.5, this organic 
compound form precipitate when met free ionic calcium revealing the presence of calcium 
deposits in the plate (sign of bone formation). Finally cells were carefully washed and 
resuspend in PBS. 
Adipogenic differentiation: 
Cells were seeded at the density of 30000 cells/cm2 in a six well plate, in particular two well 
were left in basic culture media and used as a control. The culture conditions tested to 
stimuli the cells towards an osteogenic lineage were: DMEM HG + glutarmax + 10% FCS + 
1% p/s + AsAP 0.1 mM + Dexamethasone 1µM (Sigma) + Indomethacin (Sigma) 0.2 mM + 
Insuline (Sigma) 0.01 mg/mL + 1-methyl-3-isobutyl-xantine (IBMX, Sigma) 0.5 mM. 
After three weeks of culture in condition media cells were stained for 20 min with 1-(2,5-
dimethyl-4-(2-5-dimethylphenyl) phenyldiazenyl) azonapthalen-2-ol (Oil-Red-O), this 
compound stain the triglycerides highlighting the presence of lipids storage vacuoles in the 
plate. Finally cells were carefully washed and resuspend in PBS. 
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Results 
 
Isolation 
In all isolations irrespective of isolation technique (enzymatic digestion or liver perfusion) 
colonies appeared within seven days. Examples of the morphology of cells directly after 
isolation can be found in Figure 14. Between isolation techniques no big differences 
between the enzymatic digestions solutions tested arose. 
 
  
  
Figure 14: Representative pictures of LMSCs during first days of culture. A. Presence of hepatocytes 
in the plate, red circles, (200x). B. Lymphocytes (100x) C. LMSCs (200x) D. Colony formation of LMSCs 
(40x). 
 
A B 
C D 
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Figure 15: LMSCs at passage 2 of culture (40x). Cells appear to grow as a homogenous population. 
 
Collagenase T2 enzyme was selected from all the enzymes tested and the protocol was 
further optimized for the use of this digestion media. The duration of the digestion for a 
liver biopsy (1.9±0.3g) was optimal after 1 hour. In this fashion LMSCs appear to be enriched 
in the parenchymal fraction (data not shown). Colonies appeared in one week (Fig. 14-D) 
and had a fibroblast-like shape and were abundant. On occasion some hepatocytes (Fig. 14-
A) and/or macrophages (not shown) were found directly after plating. After the first passage 
the culture become more uniform and cells show a spindle shape morphology with a small 
elongated cell body (Fig. 15). The cell body contains a large, round nucleus with prominent 
nucleolus that, theoretically, indicates high transcriptional activity. 
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Culture 
Culture conditions of the canine BMSCs were already optimized previously (Dr. M.A. 
Tryfonidou, University of Utrecht, Veterinary faculty, department of clinical sciences for 
companion animals). To determine optimal culture conditions for canine LMSCs multiple 
media types (Table 4) and additives were tested based on literature on LMSC and BMSC 
cultures. To exclude an age effect of the cells with the different culture conditions, all 
conditions were tested on juvenile (n=4) and adult LMSCs (n=8).  
 
Table 4: Culture conditions tested for growth potential of LMSCs. DMEM Dulbecco's Modified Eagle 
Medium; FCS, Fetal calf serum; bFGF, basic Fibroblast Growth Factor (FGF2); AsAp, ascorbic acid; 
p/s, penicillamine and streptomicin.  
 
Optimal growth conditions were based on viability and growth potential of the LMSCs with 
the different culture conditions. Viability was ascertained by a cell viability test (MTT) and 
growth potential by EdU incorporation quantification. Results of the MTT assay showed the 
highest viability in culture conditions with the additives basic Fibroblast Growth Factor 
(bFGF) and ascorbic acid (AsAp) (Fig. 17-17b). Although not significant, the trend indicates 
that αMEM with these culture additives also was superior to DMEM. No significant 
differences were seen between juvenile and adult LMSCs. 
Growth potential of LMSCs under different culture conditions was determined by EdU 
incorporation which can be used to determine the percentage of cells in S phase of the cell 
cycle. Representative examples of the pictures taken by the arrayscan can be seen in Figure 
16. Due to a general DNA stain with the fluorescent dye DAPI, the number of “recognized 
objects” correspond to the number of cells in a single well. The EdU labeled LMSCs in S 
phase of the cell cycle are separately determined and a percentage of dividing cells is 
calculated by the arrayscan. Results for the EdU incorporation confirmed that αMEM was 
the best media type for LMSCs; moreover the percentage of positive cells define the 
 CONDITIONS (n=6)  
1a. DMEM + 10% FCS + p/s 
Juvenile 1b. DMEM + 10% FCS + p/s + FGF + AsAp 1c. αMEM + 10% FCS + p/s 
1d. αMEM + 10% FCS + p/s + FGF + AsAp 
2a. DMEM + 10% FCS + p/s 
Adult 2b. DMEM + 10% FCS + p/s + FGF + AsAp 2c. αMEM + 10% FCS + p/s 
2d. αMEM + 10% FCS + p/s + FGF + AsAp 
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conditions with the additives advantaged compared to the ones without. Culture additives 
increased the amount of EdU positive cells by 5 fold.  
 
   
Figure 16: Representative pictures of LMSCs from the arrayscan. A. Light microscope picture of the 
cells, B. DAPI (nuclear) staining (blue) merged with the EdU positive cells (light blue), C. recognized 
objects by the arrayscan circled in green and the non-accepted objects in red.  
 
 
 
Figure 17: Viability and growth potential of LMSCs under different culture conditions.  (A) Viability 
assay with MTT (B) EdU incorporation (C) Number of identified objective (Cell number per well). 
 
 
A B C 
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Figure 17b: Viability and growth potential of LMSCs under different culture conditions.  (No age 
consideration) 
 
Overall, αMEM with 10% FCS, p/s, bFGF, and AsAp was the best condition for both BMSCs 
and LMSCs. For this reason we decided to base all the characterization comparison using 
this setting for the culture: 
αMEM + 10% FCS + bFGF + AsAp + 1% p/s. 
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Population Doublings LMSCs and BMSCs. 
To estimate the replication potential of the LMSCs a population doubling count was 
performed (See material and methods), here below the graph of cumulative population 
doublings (PDs) (Fig. 18), on the y-axes the cumulative PDs and on the x-axes the passage 
number (each passage is counted as 72h of culture). 
 
Figure 18: Cumulative population doublings of LMSCs (n=12), each passage is three days of 
culture. 
 
Interestingly if we group the samples based on the age, more specifically juveniles 
individuals (n=4) and adults (> 1 year) (n=8), we can see a significant difference in the 
replicative potential by which juvenile derived samples appear to have an advantage 
compared to adult LMSCs with a doubling of on average 2.8±0.98 versus 2.5±0.88 times per 
passage respectively (Fig. 19). 
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Figure 19: Cumulative population doublings of LMSCs, divided in two groups based on the age of 
the donor: juvenile (black circles) and adults (white).  
 
 
BMSCs do not show a similar difference between juvenile and adult samples as founded in 
the LMSCs group (Fig. 20). 
 
Figure 20: Cumulative population doublings of BMSCs, divided in two groups based on the age of 
the donor: juvenile (black circles) and adults (white).  
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Figure 21: Cumulative population doubling of LMSCs (Black circles) and BMSCs (White). 
 
In general LMSCs had a higher population doubling compared to BMSCs, with an average 
population doubling of 2.75±0.74 compared to 2.65±0.8 respectively (Fig. 21).  
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RNA profiling of LMSCs and BMSCs 
Here are reported the results obtained comparing LMSCs (n=10) and BMSCs (n=8), data is 
showed in box-plots so as to be able to look for the variability in each group. An investigation 
on the stability of the reference genes was performed with Genorm. Results indicated that 
all the six reference genes were stable and should be included. RNA samples of healthy liver 
and crude bone marrow were included as controls.  
All validated MSCs markers were found to be present in the LMSCs and BMSCs (Fig. 22). In 
general, no major differences in gene-expressions were found between LMSCs and BMSCs. 
For both cell types the expression between passages was stable, only CD90 was found to 
be increased 100 fold from passage 1 to 4 in the BMSCs group whereas for LMSCs it remain 
stable. CD73 and CD44 expression was lower compared to the other CD markers but were 
still detectable. Negative selectors (Fig. 23) resulted negative in both the groups, a little 
level of expression was found only at passage one revealing the presence of different kinds 
of circulating cells in the culture. For results of the other markers refer to the picture 
description. 
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Figure 22: qPCR results - Positive markers for MSCs selection. X-axes passages (P0->P4) of culture 
for both LMSCs (light pink) and BMSCs (Light red), in blue the whole liver and in light blue the bone 
marrow used as controls. Y-axes relative gene expression (Note: Scale are different in each graph). 
All the markers presented in this panel result positive in all the groups; in particular comparable 
levels of expression between LMSCs and BMSCs were found for all the markers; moreover CD73 and 
CD44 remain detectable in both the cell types even if at a very low level of expression. 
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Figure 23: qPCR results - Negative markers for MSCs selection. Negative markers are used mainly 
to test the absence of other cells present in the bone marrow that might contaminated the culture. 
In the first row of graphs CD45 and CD235a are specifically expressed in differentiated 
hematopoietic cells the first and in erythrocytes the second.  CD11b and CD14 are both expressed 
by macrophages whereas CD19 is a lymphocyte marker. Moreover CD74 (DLAGR) correspond to the 
invariant chain of the major group of histocompatibility of class II, is known to be negative in 
undifferentiated MSCs. Overall all this six markers appear to be negative for the samples tested. 
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Figure 24: qPCR results - Other MSCs Markers. This CD- markers appear to indicate a difference 
between the LMSCs and the BMSCs. CD144 is an endothelial cell marker that show an abundance 
expression in the LMSCs group, moreover CD146 (MCAM), another marker associated also with 
vascular cells, appear to distinguish different MSC cell populations (Iwata M, 2013).  
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Once the MSCs qualification was assessed we investigate the putative differences between 
the LMSCs and BMSCs focusing on specific Liver’s markers such us CK18, CK19, Onecut1 and 
Albumin (CSA) (Fig. 25).  
 
Figure 25: qPCR results - Liver specific markers. LMSCs appear to retain a liver specific imprinting 
by showing expression of markers such as CK18 (Hepatocyte marker) or CK19 (liver progenitor cell 
marker); no expression of ALBUMIN or ONECUT1 were detected in both groups, moreover also 
ONECUT2 appears to be negative in the MSCs population (Data not shown). CD255 and CD266 which 
are on order TWEAK (TNF-related weak inducer of apoptosis) and TNF14 (Tweak receptor), show 
comparable level within the MSCs groups, the first a very low level whereas the second higher 100 
fold. 
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Embryonic stem cell markers have also been tested in this gene expression analysis. 
Markers such as NANOG and OCT4 were not detectable in both the sample groups (data 
not shown), here below are reported the results for SOX2, LIN28 and LGR5; CD133 is not an 
embryonic stem cell marker but is thought to be an adult stem cell marker of progenitor 
cells from different tissues (Fig. 26). 
 
 
Figure 26: qPCR results - Pluripotency markers. Low level of expression were detectable for all the 
markers included in the panel. To note little expression of LGR5 was detectable only in the LMSCs 
group, as a confirm LGR5 appear quite positive in the liver whereas in the bone marrow absent. 
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Moreover we were interested in investigating the putative immune modulatory potential 
of these cells, to do this a selection of genes was made to look for possible pathways 
activation that would act on the immune system cells such as T-cells. One of the questions 
was to validate the data reported for the human derived LMSCs (Fouraschen SM, Secreted 
factors of human liver-derived mesenchymal stem cells promote liver regeneration early 
after partial hepatectomy., 2012) in which they looked in particular in the prostaglandin 
pathway (Table 5 – Fig. 27). 
 
Table 5: Markers tested for immunogenic potential of LMSCs and BMSCs. 
 
  
Marker Function 
PTGS1 Is a Cyclooxygenase that catalyze the conversion of arachinodate to 
prostaglandin. The encoded protein also regulates angiogenesis in 
endothelial cells. 
PTGS2 Also known as COX2 it catalyze the rate-limiting step of prostaglandin 
production. While COX1 is in fact expressed constitutively, PTGS2 is 
inducible. 
PDL1 
(CD274) 
Involved in the costimulatory signal, essential for T-cell proliferation and 
production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent 
manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine 
production 
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Figure 27: qPCR results - Immune modulatory related markers. CD274 (PDL-1), PTGS1 and 2 are 
all genes involved in the prostaglandin production and signal pathway, the expression of these 
markers suggest a putative MSCs modulation activity on T-cells behavior as well as others cell types.  
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Fluorescent activated cell sorting (FACS) analysis  
A titration assay was performed for all antibodies, the optimal amount of is depicted in 
table 6. 
Table 6: Results of the titration experiment. All the antibodies were tested at least for three 
different amount (2, 5 and 10µL) so as to look for the optimal concentration. 
Antibody Optimized amount for staining (/5x105cells) 
CD105 5 µL 
CD166 5 µL 
CD29 5 µL 
CD90 5 µL 
CD45 10 µL 
Rat IgG 2.5 µL 
Rabbit IgG 1 µL 
Mouse IgG 2.5 µL 
 
Once the corrected amount of antibodies was found the staining has been repeated on 
multiple samples (At the current time n=7) of both LMSCs and BMSCs, in particular the 
analysis was performed on cells sample at passage 2 of culture. As suggested also from the 
pictures, LMSCs and BMSCs, appeared to be comparable base on structure and 
morphology, this fact allowed the use of only one setting for the analysis, in particular the 
Forward scatter (FSC) and the side scatter (SSC), FSC correlates with the cell volume and 
SSC depends on the inner complexity of the particle (i.e. shape of the nucleus).  
The 7-Amino-actinomycin D (7-AAD) staining, used to gate in only alive cells, reveal a 
percentage of dead cells of, on average, 20% (Fig. 28). 
 
Figure 28: Example of gating. Y-axes fluorescence registered for 7-AAD, X-axes FSC. The 7-AAD 
reveal the dead cells present in the samples, in particular the blue rectangle correspond to the gate 
applied in the analysis and for this sample it included 82.98% of alive cells. 
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Here below are reported the results obtained for the FACS analysis (Fig. 29); the protein level 
validation confirm the expression of the proposed selectors mesenchymal markers (CD105-CD90-
CD29-CD166) and the lack of hematopoietic marker expression (CD45).  
 
 
Figure 29: FACS analysis results. In this pictures are exemplified the first results obtained on both 
LMSCs and BMSCs for the markers listed in Table 6. In particular each box show the overlay of the 
histograms registered for the unstained and the host-specific isotype control (both negative 
controls) together with the marker in analysis. All the markers result positive ad exception of CD45 
that indeed is consider a negative marker of selection for MSCs. Note: Y-axes cell count, X-axes 
wavelength. 
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Differentiation assay 
Pilot experiments of the differentiation assays showed positive results for all the lineages 
tested; here are reported representative pictures for both LMSCs and BMSCs (Fig. 30-31-
32). Replicates of the experiment are now subject of work so as to reach a statistical 
significant indication. 
 
   
Figure 30: Adipogenic differentiation. A. negative control. B. Cells positive for the Oil Red Staining, 
in particular is possible to appreciate the marked lipid droplets inside the cells. 
 
   
Figure 31: Osteogenic differentiation. A. Negative Control. B. AlzarinRed Staining, cells show 
mineral deposit formation. 
 
 
 
 
A B 
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Figure 32: Chondrogenic differentiation. Pilot experiment run on BMSCs. Safranin-O (in red) stain 
proteoglycan which indicate the formation of cartilage in the pellet. The present pilot experiment 
will be run on multiple samples of both LMSCs and BMSCs so as to evaluate the chondrogenic 
potential of MSCs. 
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Discussion 
 
The aim of this thesis was to demonstrate the possibility to isolate a mesenchymal stromal 
cell population from the canine liver. To reach this goal the investigation included the 
optimization of an isolation protocol of MSCs from canine liver and the characterization of 
the isolated cells in comparison with bone marrow derived MSCs. In this part of the thesis 
these aspects will be addressed and discussed. 
 
van der Laan et al. were the first to describe the isolation and the characterization of human 
MSCs derived from the liver (LMSCs). More specifically, LMSCs were isolated from the liver 
preservation fluid in which the liver is stored prior to transplantation into a new host (Pan 
Q, 2011). In the present study we have shown the possibility to isolate LMSCs from the 
canine liver. Moreover we have shown that the isolation of LMSCs can be performed with 
two approaches: an enzymatic digestion and a perfusion. Being able to isolate a similar liver 
derived MSCs population confirm the presence of a MSCs population also in the canine liver.  
The use of the dog as a model for the study of human diseases, in particular liver associates 
diseases, offer several advantages if compared with others such as the mouse. As already 
discussed in the introduction the long life span and the size of the organ itself show a high 
resemblance the human situation. Moreover the genetic background, arose by centuries of 
breed selection, offer a privileged model for the study of simple inherited diseases. 
Although both the enzymatic digestion and the perfusion resulted in a successful isolation 
of LMSCs, the enzymatic isolation turned out to be the best eligible between the two. This 
is mostly due to the possibility to use stored liver biopsies especially considering that MSCs, 
theoretically, can be used for allogenic treatment and therefore do not have to be derived 
from the same individual. The possibility of storing samples and preserve large amounts is 
indeed a key requirement to raise new cell based therapies. 
 
We observed that the plastic adherent cells obtained after isolation can be expanded in 
vitro, reaching numbers that would be sufficient for clinical purposes (i.e. (Karussis D, 
2010)). In particular LMSCs were cultured up to passage 9 without any indication of 
senescence. The most frequent condition used for the culture of MSCs is DMEM HG (High 
glucose), in both dog and human, with the addition of 10% FCS, however in our lab canine 
BMSCs were cultured in αMEM; in this regard we decided to test the two conditions to see 
56 
 
which appear to be more suitable for the culture of the liver derived MSCs. In particular we 
tested the viability of the LMSCs in the culture by performing a MTT staining, and as a test 
for the variation of the replication potential we performed an EdU staining assay. From both 
the experiments the outcome show a superiority of the αMEM media, moreover both the 
experiments confirm the positive effect of the addition of bFGF and AsAp to the culture. 
AsAp is supposed to function as a scavenger for radical oxygen species, bFGF on the other 
hand is a well-known mitogen (Ng F, 2008). Their addition appear to determine a positive 
effect on both the survival and the replication ratio (see EdU results) of the LMSCs. From 
these results we decided to set the αMEM + 10% FCS + p/s + 0.1ng/mL bFGF + 0.1 mM AsAp 
as our standard culture condition; similar results were obtained for BMSCs that as already 
mentioned were cultured under the same conditions. In addition we shown the possibility 
to culture these cells for a long term without any indications of consistent decrease of 
proliferation, comparing our results with indication reported for canine adipose-derived 
MSCs (Vieira NM, Isolation, characterization, and differentiation potential of canine 
adipose-derived stem cells., 2010) as well as other BMSCs (Takemitsu H, 2012) it appears 
that the use of additives for the culture might not only improve the growth of the cells but 
prevent the loss of the undifferentiated state of MSCs. Interestingly Choi et al. (Choi SA, 
2013) on the other hand, imply bFGF and the epidermal growth factor (EGF) for the culture 
of canine amniotic fluid derived MSCs, in this fashion the cells show a consistent decrease 
in growth potential from passage 6. These founding stress once again the existence of 
differences between MSCs derived from different sources and more precisely the abundant 
heterogeneity of these populations.  
 
Our results show for both liver and bone marrow derived cells a comparable replication 
potential, furthermore both of them show a decrease in the PD value associated with later 
passages suggesting that they own indeed a good ability of self-renew even if not 
comparable with a true stem cells population. In the first days of culture a little amount of 
macrophages and hepatocytes are detectable in the plate however already during early 
passages the cell population become more homogenous. Already in P2 one single kind of 
cell morphology was detectable in the plates, a spindle shape cell (Fibroblast like). 
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At this point we could clinch to have in culture two population of cells derived from different 
tissues, both of which appear to be plastic adherent and show a nice self-renew capacity, 
and possess a fibroblast like shape. Although all these information might straightaway lead 
to the idea that we have a true mesenchymal cell population in culture, an investigation of 
the gene expression profile is required for a true characterization. In particular, as already 
mentioned before, the ISCT years ago proposed a minimal set of criteria, which is agreed to 
be required to name a cell MSC (See table 1). The lack of exclusives markers for MSCs and 
the multiplicity of differences that arose studying MSCs derived from different species and 
sources make the venture of the characterization of MSCs more difficult, however the 
combination of few markers (Such as CD105+-CD90+-CD166+-CD29+-CD45-) allow the 
isolation of a quite homogenous MSC cell population. 
 
In the present study we confirmed the mesenchymal identity of both liver derived and bone 
marrow cells. Each LMSCs and BMSCs isolated from the dog are positive for mesenchymal 
markers such as: CD105, CD90, CD166 and CD29 (see results section for more detail); and 
negative for hematopoietic (CD45) or others blood cells markers (CD11b-CD14-CD19-
CD235a). In particular we purposed a panel of antibodies for the protein level validation on 
flow cytometry of the following genes: CD105, CD90, CD166, CD29 and CD45. In both the 
MSC populations a uniform expression of the markers was detected with on average 85% 
of cells positive the tested markers and fully negative for CD45. The differentiation trough 
the three lineages (chondrogenic, adipogenic and osteogenic) is the latter requirement for 
the definition of MSCs, although the results lack of the statistical significance, positive 
results were obtained in multiple pilot experiment. Is of course one of our priority to show 
the goodness of these tests. 
 
The qRT-PCR analysis revealed differences between the BMSCs and the LMSCs; while BMSCs 
show on average an increment of the expression of mesenchymal markers moving from P0 
to P3, (i.e. CD90) LMSCs show a more stable trend; interestingly comparing the cells type at 
P4 almost all the markers have very similar levels of expression. Those differences might 
indicate the casual selection of specific subpopulation during the culture, on the other hand 
they might define a true difference between the cells population.  
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Interestingly Requicha et al. (Requicha JF, 2012) showed for canine adipose tissue derived 
stem cells (cASCs), that the expression of CD105, CD73 and CD90 decrease consistently 
during the passages, suggesting a slow loss of potential which is remarked also by the 
decrease of pluripotency markers. Similar results were reported by Vieira et al. (Vieira NM, 
Isolation, characterization, and differentiation potential of canine adipose-derived stem 
cells., 2010), again on cASCs that this time appear to lack of the expression of CD105 and 
CD73. A first possibility is of course the existence of a difference between adipose derived 
cells and others MSCs in the dog; another possible explanation for this differences between 
our results and cASCs ones is the lack of bFGF in the culture, both the groups referred in 
fact cultured the cells in DMEM (HG) + 10% FCS; this growth factor indeed might boost the 
stemness of the cells allowing them to retain further a more permissive phenotype.  
Moreover, CD73 and CD44, which are also reported to be positive MSCs markers (Zhou P, 
2013) do not show such a high level of expression but still appear to be detectable in all the 
samples, CD44 is a ubiquitary protein which is able to bind different extracellular matrix 
components; even more CD44 appear to be able to trigger the activation of T linphocytes 
suggesting a putative modulatory interaction (Estess P, 1998).  
CD144, vascular-endothelial cadherin, is an endothelial progenitor cell marker considered 
to be important for the vasculogenesis process (Hager G, 2013). This gene appear to be 
strongly expressed in LMSCs whereas BMSCs do not express it; this might suggest an affinity 
between our LMSCs and endothelial progenitors cells, further investigation should look 
more in detail this possible link between these cell types. Once again the qPCR results 
discussed above resemble a mesenchymal phenotype for both liver derived and bone 
marrow derived cells. 
Furthermore we tested the expression of liver specific markers so as to investigate whether 
the LMSCs show a liver specific imprinting or appear comparable with the bone marrow 
ones. Interestingly only LMSCs appear positive for markers such as CK18 and CK19, the first 
Is a hepatocytes cell marker whereas the latter is consider to associate with liver progenitor 
cells, confirming the presence of a liver imprinting. This suggest that LMSCs might be more 
suitable for the treatment of liver diseases, is important to take in mind that these results 
might underline a spontaneous differentiation of LMSCs towards an hepatic cell fate and 
not a positional signature. Taking in consider also the results obtained for CD266 (also 
known as TNF14), which is expressed specifically in liver progenitor cells it follow that there 
might be a link with progenitor cells. Further investigation should look in details on the 
similarities of these population to assets whether they really constitute two different 
populations. 
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Embryonic pluripotency markers such us OCT4 and NANOG were not detectable in the 
analysis (Data not show), on the other hand we were able to register some adult stem cells 
markers such as LIN28, SOX2 or LGR5. The detectable expression of LGR5 in particular was 
found only in LMSCs; LGR5 is known to be expressed in liver progenitor cells and in other 
progenitors cells in the body (Clevers, 2013), this in turn might suggest again a relation 
between LMSCs and liver progenitor cells but also open new possibility for the use of these 
cells. Moreover LGR5 has been proposed recently to be a marker of selection for adult stem 
cells with high potential, cells LGR5+ appear able to constitute organoids in vitro when 
cultured in matrigel. Organoids are 3D structure that appear to enhance the growth 
possibility and may have a beneficial effect for cell therapy if compared with single cells 
based treatments.   
 
The homogeneity of the culture is an important requirement for the application of MSCs 
for medical purposes.  Apparently both the LMSCs and the BMSCs comply in this fashion, 
moreover one consequence of their showing close similarities is the prospective of being 
able to use them interchangeably. These similarities include morphology and growth 
potential and gene expression profile. Of course we must not forget that even if both the 
populations studied appear uniform a single cell derived colony will constitute the true 
optimal population for clinical purposes, in this regard we proposed a panel of antibodies 
that could constitute a good level of selection for the sorting procedure. One of our working 
hypothesis was that LMSCs are really resident in the liver and are not perhaps circulating 
BMSCs. The evidence of putative circulating BMSCs has already been shown in literature 
(Zvaifler NJ, 2000). As already mentioned we investigated different liver specific markers 
founding detectable expression of some of them only for LMSCs. This observation dwindle 
the circulating cell theory,  at least for the liver derived we investigated; although is still 
possible to argue that cells can migrate and then acquire a specific in loco imprinting, overall 
a different origin possibility seems more conceivable than a migration one.  
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MSCs are nowadays a widespread studied type of cell, this preponderance for the use of 
MSCs arouse from some of the features that are shown exclusively by these cells; for 
example several studies underlined a high immunogenic potential. First the lack of the MHC 
Class II (CD74) together with the secretion of multiple bioactive molecules prompt an 
important modulation activity that these cells might possess. In the present study we 
wanted to test whether our LMSCs and BMSCs lack of DHLAG, which is also one of the 
minimal criteria for the definition of MSCs, and if the activation or not of the prostaglandin 
pathway. As already discussed in the introduction prostaglandins show a high modulatory 
capacity on both the adaptive and the innate immune system. Our results confirmed for 
both the MSCs populations the absence of DHLAG; this open already several possibilities 
and remarks once more time a possible privileged state of MSCs for clinical purposes, this 
indeed open the possibility of using LMSCs or BMSCs in both autologous or allogenic 
treatment. Moreover also the expressions of genes such as PTGS1, PTGS2 or CD146, 
founded in these canine MSCs, suggest a putative effect on cells of the immune system and 
more. 
 
As already mentioned multiple studies ( (Pan Q, 2011) (Fouraschen SM, Secreted factors of 
human liver-derived mesenchymal stem cells promote liver regeneration early after partial 
hepatectomy., 2012)) have already investigate the effect human LMSCs on the proliferation 
and maturation of T-cells, for this reason is one of our ongoing research the repetition of 
the experiments they have performed, in particular we are going to test the effect of both 
LMSCs and BMSCs on the proliferation of selected T-cells populations.   
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Conclusion 
 
MSCs appear to possibly be isolated from any tissue or organs; in this study we demonstrate 
the potential to isolate a population of liver derived MSCs in the canine model. In particular 
we investigate two main approaches of isolation: an enzymatic digestion and a perfusion 
based one. The latter approach, if compared with the methods used previously in the 
human model (Pan Q, 2011), might suggest similarly the presence of circulating MSC in the 
liver ore their close relation with the vascular system. Both of the overtures have been 
successful and also highly comparable, this prompt the idea that indeed both of them 
allowed the isolation of the same population of cells. Moreover here we compared our 
analysis between MSCs derived from the liver and from the bone marrow, once again the 
results in the multiple test were highly comparable. In this theme the use of the dog as a 
model of study allows the comparison of cells derived from same individuals; the possibility 
of avoiding the consideration of individual variability gives strength to the analysis and to 
the conclusion we can obtain from. 
Cells have been proven to resemble the minimal criteria proposed by the ISCT (Horwitz EM 
& Therapy., 2005) for the definition of MSCs. Moreover the investigation of gene expression 
profile remarked the presence of similarities as well as differences such us the putative liver 
imprinting that appear to be retained in LMSCs. As already discussed the immunogenic 
potential of MSCs is one of the key properties of these cells for clinical purposes, in this 
study we showed the lack of the CD74 which might allow the implement of MSCs for cell 
transplantations purposes without trigger the immune reaction, furthermore we 
investigated the putative activation of the prostaglandins pathway that indeed will confirm 
once again a possible active role in secreting different bio-active molecules.  
New investigations are required to understand if one of this two cell sources offer the 
possibility to isolate a superior modulatory-base MSC fraction. On the other hand is possible 
that these cells will resemble comparable data, in this prospective more attention should 
be focus on the liver level of imprinting showed from the LMSCs, this could in turn provide 
a more suitable phenotype for the cure of several liver diseases. 
All these consideration raise more questions on the true identity of these cells: are these 
high similarities the result of an in vitro induction of a MSCs phenotype or this cells retain a 
common phenotype independently from the site of derivation? Recently new concepts and 
consideration have been proposed in this regard: (Paolo Bianco, 2013) the author stress 
one more time the need for more consistent validations on the true nature of MSCs derived 
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from different tissues. In particular one of the first concept he introduced is a clear 
distinction between our concept of MSCs and cells derived from the bone marrow (which 
he names skeletal stem cells) which might participate in the mesengenic process and derive 
from a common progenitor of hematopoietic stem cells. Although all the changes he 
introduces in both the definition and the characterization of these cells I agree on his 
tentative of finding more concrete assays to validate the cell phenotype. In particular the 
author stress the need for in vivo functional assays to test the real potential of the cells, the 
use of only in vitro tests is indeed quite confusing because might resemble an artifact more 
than a true potential. Even more, despite from the classification or the nomenclature we 
would like to apply, it appear fundamental the need for the introduction of system that will 
allow the use of a more homogenous population. Few months ago (Yo Mabuchi, 2013) 
described the presence of at least three different subpopulations of mesenchymal cells in 
the bone marrow; he also show how a stringent selection trough specific markers can 
allowed to sort them revealing different properties for each sub population. In the view of 
a concrete use of Mesenchymal stromal cells for cell therapy this step is undoubtedly 
required. The lack of this step mark all the present clinical trials inconsistent, the 
heterogeneity of the culture will indeed reveal incongruent results and make the study of 
this cells population harder and un-expectable. I would like to conclude underlying another 
feature showed by MSCs that in turn could, in my opinion, open new questions and 
investigations: considering MSCs either a true population or an in vitro artefact, several 
studies reveal the possibility of differentiating these cells towards almost any kind of cell 
fate; this characteristic, not considering the reprogramming approach, it appear unique of 
this population. This high plasticity in moving towards different cell’ kinds should 
theoretically reflect an high plasticity on the epigenetic signature, in this fashion it would 
be really interesting to understand which are the factors that lead to this “plastic” state; 
these hypothetic factors could indeed constitute key players to develop new tools for the 
reprogramming process. 
  
63 
 
Annexes 
 
Protocols 
1. Isolation of LMSCs from frozen chopped liver tissue  
 
1. From the liquid nitrogen storage, place vials into the water bath (37°C) to thaw the 
chopped liver tissue. Place the sample into about 10mL of prewarmed media (i.e DMEM w/ 
1% FCS) in a 50 mL conical tube. 
2. If a pellet of chopped liver does not appear spin down briefly (250g max). Remove 
supernatant and wash the chopped liver tissue with 10 mL prewarmed Hanks BSS two times 
or until the media turn clear (if the media remains milky DNase treatment could be 
performed). 
3. Remove the supernatant and add 23mL of digestion media (collagenase type 2 or Liberase 
or Dispase, check material and methods for details). Place in the water bath at 37°C and 
shake intermittently. Every 20 min mix the chopped liver tissue with a 10mL pipet and check 
the supernatant for cells. (Generally is necessary to incubate 1 hour or more maximum 2h 
incubation). Note: If there are no cells in the supernatant and the incubation exceeds 2 
hours, remove media and add fresh digestion media. 
4. Filter the supernatant through a 70µm strainer. 
5. Centrifuge at 50g for 10'. Collect both the supernatant and the pellet (parenchymal 
fraction)  
6. Centrifuge the supernatant at 200g per 5'. Collect only the pellet (non parenchyamal 
fraction) 
7. Resuspend in warm expansion media (i.e. DMEM w/ 10% FCS and p/s) 
8. Place into culture stove, incubate the plates at 37°C with 5%CO2 in a humidified chamber 
without disturbing them. The day after, remove the non-adherent cells and the debris that 
accumulate on the surface of the dish by changing medium and replacing with fresh 
complete medium. 
9.  Afterwards change media twice a week until cell growth is observed. 
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2. Isolation of LMSCs through Liver “perfusion” 
 
1. Perfuse the liver’s lobe with 250mL of cold Hank’s BSS and aliquot the perfusated in 50mL 
conical tubes. 
2. Centrifuge at 200g for 5 minutes, resuspend the pellets in prewarmed media and pull 
together all the fractions in a new 50mL tube. 
3. Centrifuge at 200g for 5’. 
4. Resuspend in 10mL of prewarmed media (i.e. DMEM + 1% FCS + p/s). 
5. Add 10mL of Ficoll to a new 50mL falcon tube. 
6. Layer the 10mL of your solution on top of Ficoll being careful to minimize mixing with 
Ficoll. 
7. Centrifuge at room temperature (15 - 25˚C) for 30 minutes at 400g with brake off. 
8. Remove and discard upper plasma layer without disturbing the plasma-Ficoll interface. 
9. Remove and retain mononuclear cell layer at the plasma-Ficoll interface without 
disturbing the erythrocyte/granulocyte pellet. 
10. Wash mononuclear cells: centrifuge at 200g for 5’ and resuspend in fresh media.(Repeat 
this step twice). 
11. Centrifuge at 200g for 5’, count the cells and place in culture stove. 
12. Change the media after 24 hours, afterwards change media twice a week. 
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MTT assay 
 
1. Harvest the cells and count them, plate the cells in a 96 well plate format at a density 
of 10x103 cells/cm2 
 
2. After 24h change the media into the conditions and culture the cells for 48h. 
 
3. Add 20 µL of freshly prepared filtered sterilized MTT solution (5mg/mL) to each well 
containing 100 µL medium. As a control, include wells without cells.  
 
4. Place the plate back in the culture stove at 37°C for 2 hours. 
 
5. Remove the media by decanting (discard the media in a chemical waste bin) and add 
50 µL of filtered sterilized DMSO to each well incubate for 10 min on an orbital shaker 
(1,000 rpm) (this will lyse the cells and free the formazan crystals). 
 
6. Measure absorbance in the plate reader at 595nm and a reference at 650 nm. 
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EdU staining 
1. Harvest the cells and count them, plate the cells in a 96 well plate format at a density of 
10x103 cells/cm2 
 
2. After 24h change the media into the conditions and culture the cells for 48h. 
3. EdU Pulse: add 11 µL of EdU to culture medium: 10µM for 2 hours (For the negative control: 
non-pulsed, add 11 µL of media).  
4. Wash cells 2x in PBS-Tween 0.1%, leave 100 µL of PBST on cells. 
 
5. Fix cells in 3.7% PFA and permeabilise with 0.5% Triton for 10min at RT. Prepare fresh a 2x 
fixating solution with 8% PFA and 1% Triton. 
 
6. Add 100 µL of fixating solution to the wells (containing 100 µL of PBST) by dripping it on 
slowly. Incubate for 10 min at RT. 
 
7. Remove fixative, add 200 µL PBS, store plate at 4°C. 
 
8. Seal plate with parafilm, fixed plate can be kept in fridge for 1-2 weeks before staining. 
 
9. Wash cells 1x in EdU staining buffer 100 µL per well (100mM Tris pH 8.5 + 1mM CuSO4) 
without azide or ascorbic acid. 
 
10. Stain cells with EdU staining buffer + 5µM AF488-azide + 100mM Ascorbic acid (prepare 
fresh). 
 
11. Add staining mixture to cells immediately after preparation: 45µL/well. 
 
12. Incubate for 30’ at RT in the dark. 
 
13. Wash 2x with PBST-Tween 0.1%. 
 
14. Stain cells with DAPI: 50 µL /well, DAPI 1:4000. 
 
15. Incubate at RT for 30’ in the dark. 
 
16. Top up the wells with 150μL PBS (preferable filtered PBS, has less crystals). Check plate under 
microscope; perform image acquisition/analysis with arrayscan preferably on the same day. 
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qPCR reaction and analysis 
 
For the investigation of the gene expression profile of the LMSCs and the BMSCs a fraction of, on average, 
100’000 cells was collected each passage and lysed in RLT. Once RNA was purified and cDNA reaction 
performed all the samples were diluted 10x and 50x. The 10x diluted were pooled together (5µL each) so 
as to make the standard pool (S1) which was subsequently diluted 4-fold up to S7. The 50x diluted were 
used for the analysis.  Master Mix was prepared using iQ SYBR green SuperMix (BioRad) with a primers 
concentration of 10µM and milliQ to reach volume, so as to have 6µL of master mix per reaction.  All the 
analysis was performed in a 384 well/plate format (Hard-Shell® 384-Well PCR plates, BIORAD cat. No. HSP-3805). 
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Cell staining and FACS analysis 
 
For FACS analysis purposes a fraction of cells of specific passages (P2 – P4), minimum 500x105 cells, has been 
frozen and plated back in culture one two days before the analysis. Cells were stained for different markers 
with primary antibodies directly PE- conjugated (See Materials and methods Table 6) as described in the 
protocol reported below. 
 
1. Harvest, wash the cells with PBS and adjust cell suspension so as to have a minimum of 50x105 
cells per test.  
2. Centrifuge at 1,200 rpm for 7 minutes. 
3. Optional: Fc-block cells with blocking IgG (1 μg IgG/10^6 cells) for 15 on ice. Note: Do not wash 
excess blocking IgG from this reaction.  
4. Distribute your blocked cells 50µL/sample/stain (first refill up with FACS-buffer to have 
50µL/sample) (60µL/sample can be better depend on the cells count) 
5. Add 0.1-10 μg/mL (correct all the volumes with FACS buffer to have the same end volume for 
all) of the primary labeled antibody in PBS w/ 3% BSA, mix by flicking the tube.  
6. Incubate for at least 15’ on ice. (This step will require optimization, other options are 
incubation at room temperature or at 4°C). 
7. Wash the cells 2 x by centrifugation at 1200 rpm for 7 minutes at 4°C (First time add 150µL and 
the second time 180µL of FACS buffer) and resuspend them in a minimum of 180 µL of ice cold 
FACS buffer. Keep the cells in the dark on ice or at 4oC in a fridge until your scheduled time for 
analysis. 
8. Add 5 µl 7-AAD (0.25 µg) to the solution and incubate for 5 minutes.  
9. For best results, analyze the cells on the flow cytometer as soon as possible (at least same day). 
 
FACS buffer composition (i.e. for 50mL):  
o PBS (1x)   49 mL  
o FCS (10%)     1 mL  
o Sodium azide (01% w/v) 50 mg 
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Sequencing 
 
1. For each reaction, add the following reagents to a separate tube: 
 Terminator Ready Reaction Mix    1 µL 
 Template: 10x diluted qPCR product    3 µL 
 Primer (3.2 pmol)      1 µL 
 5x Sequence buffer      2 µL 
 MQ        4 µL 
       Total volume  10µL                        
2. Mix well and spin briefly. 
3. Place the tubes in a thermal cycler (Cycle sequencing on the MJ PTC-100): with heated lid. 
4. Set the thermal cycler so as to have for 25 cycles:                                                      
- rapid thermal ramp to 96°C 
- 96°C for 30 sec. 
- rapid thermal ramp to 50°C 
- 50°C or 55°C for 15 sec. (depends on the annealing temperature in qPCR) 
- rapid thermal ramp to 60°C 
- 60°C for 30 sec (+/- 1 min/ kb) 
 
5. Rapid thermal ramp to 4°C and hold until ready to purify. 
6. Spin down the contents of the tubes in a micro centrifuge. 
7. Proceed to the “Sephadex purification”. 
8. Load dry Sephadex into all 96-wells of a Multiscreen MAHV plate using the column loader as 
follows: 
 Add Sephadex G-50 to the Column Loader. 
 Remove excess resin off the top of the column loader with the scraper. 
 Place Multiscreen MAHV plate upside-down on the top of the Column Loader. 
 Invert both Multiscreen MAHV plate and the Column Loader. 
 Tap on top or side of the Column Loader to release the resin. 
 
9. Using a multi-channel pipette, add 300 µL MQ water to each well to swell resin. Incubate at 
room temperature for 3 hours. - Once the mini-columns are swollen in multiscreen plates, they 
can be stored in the refrigerator at 40C for up to two weeks, by tightly sealing the plates with 
parafilm. – 
10. Place a Centrifuge Alignment Frame on top of a standard 96-well microplate, then place the 
MAHV plate on the assembly, without lid. 
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11. Centrifuge at 1900 rpm for 5 min. to pack the mini-columns. 
12. Carefully add 10-20 µL MQ water to the sequencing reactions (10 µL) and pipet everything to 
the center of the columns. 
13. Tape off the unused mini-columns. 
14. Place the MAHV plate (without the lid) on top of a sequencing plate (a MicroAmp™ Optical 
96-Well Reaction Plate) and centrifuge at 1900 rpm for 5 min. 
15. Proceed to Electrophoresis on the ABI Prism 3130xl sequencing machine. 
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Differentiation 
 
Osteogenic differentiation 
1. Wash cells with 10mL diluted HBSS (10% HBSS, 90% MQ). 
 
2. Trypsinize the cells (TripLE Express), centrifuge at 1500 rpm for 5 min and count the cells.  
 
3. Plate out the cells at a density of 3,000 cells/cm2 in a 6-well plate  
 
4. Add differentiation media (see further), refresh the media every 2/3 days (usually twice a 
week); culture for 3 weeks and then proceed with the Alzarin Red Staining 
 
Media composition 
Stock media: DMEM HG + glutarmax + 10% FCS + 1% p/s  
Add fresh (i.e. for 5mL):  
 25 µL  AsAP   20mM    0.1 mM 
 1,25 µL  Dexamethasone  0.02 mM   0.1 µM 
 25 µL  β-Glicerol-phosphate  2 M     0.2 mM 
 
 
Alizarin Red Staining 
Prepare Alizarin Red solution (Solution can be stored at Room Temperature): 
- Dissolve 2g Alizarine Red in 60 mL distilled water 
- Adjust to pH 5.5 with 0,5% NH4OH 
- Adjust to 100 mL final volume 
- Filter the solution trough 0.22µm filter 
 
1. Wash all the wells once with HBSS 
 
2. Fixate the cells with 1 mL NBF (Neutral buffer formaline)/well and incubate at RT for 30 min 
(in a fume hood) 
 
3. Remove NBF and wash twice with distilled water (carefully) 
 
4. Incubate 20 minutes with Alizarine Red solution at RT (i.e. 1 mL/well (6 well plate)) 
 
5. Remove staining solution carefully, rinse 2-3x with distilled water, remove supernatant 
carefully, place on shaker 
 
6. Add distilled water for microscopy observation and photography (The stained cells can be 
stored under PBS - closed with parafilm in the fridge) 
Final concentration 
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Adipogenic differentiation 
 
1. Wash cells with HBSS  
 
2. Trypsinize the cells (TripLE Express), centrifuge at 1500 rpm for 5’ and count the cells.  
 
3. Plate out the cells at a density of 3000 cells/cm2 (i.e. 150.000 cells/well in a 6-well plate) 
 
4. Add differentiation media (see further), refresh the media every 2/3 days (usually twice a 
week); culture for 3 weeks and then proceed with the Oil-Red Staining 
 
Media composition 
Stock media: DMEM HG + glutarmax + 10% FCS + 1% p/s  
Add fresh (i.e. for 5mL):  
 25 µL  AsAP    20mM   0.1 mM 
 1,25 µL  Dexamethasone   4 mM        1    µM 
 25 µL  Indomethacin   40 mM     0.2 mM 
 5 µL  Insuline    10 mg/ml  0.01 mg/mL 
 2.5 µL  1 methyl-3- isobutyl xantine  (IBMX) 1M    0.5 mM 
 
Oil-Red Staining  
Prepare Oil-Red-O working solution (fresh every time) 
   - Mix 6 mL Oil-red-O with 4 mL distilled water 
   - Wait for 10 minutes, RT 
   - Filtrate the solution 
1. Wash all the wells once with HBSS. 
 
2. Fixate the cells with 1 mL NBF/well and incubate at RT for 30 min (in a fume hood). 
 
3. Remove NBF and wash twice with HBSS. 
 
4. Stain cells with 1 mL / well Oil-red-O solution for 20 minutes, incubate for RT  
 
5. Remove staining solution carefully 
 
6. Wash with HBSS until the media turns clear 
 
7. Rinse in distilled water for microscopic observation and photography 
 
 
Final concentration 
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Product list 
 
Isolation 
 Collagenase T2: Worthington, cat. No. 
41C12180 
 Liberase TM: Roche Diagnostic, 06401127001 
 Dispase: Gibco, cat. No. 17105-041 
 Ficoll: Stem cell technologies, cat. No. 07957 
Culture 
 αMEM: Invitrogen 22561-021 
 DMEM: Gibco, cat. No. 31966-21 
 HBSS: Hanks` BSS (1x) without Ca & Mg without 
Phenol Red, PAA Laboratories H15-009 
 Old FCS: Fetal Bovine Serum Gold, PAA 
Laboratories A15-151 
 FCS, Gibco, 16000-044 
 p/s, PAA Laboratories P11-010 
 FGF,  
 AsAp: Sigma A8960, B272, Mw = 289.54 g/mol  
 Dissociation reagent TrypLE express, GIBCO cat. 
No. 12604-013 
 DMSO, UVASOL, cat. No. 67-68-5 
 
Additives for Differentiation  
 Heparin: Sigma Aldrich cat. No.  H3149 
 β-Glycerol-Phosphate, Sigma cat. No. G6376 
 Dexamethason, Sigma cat. No. D1756, Mw = 
392.46 g/mol 
 Proline, Sigma cat. No. P5607, Mw = 115.13 
 ITS, 1 ml per 100 mL medium 
 Indomethacin, Sigma cat. No. i7378, Mw = 
357.79 
 Insulin, Sigma cat. No. i9278 (5 mL) 
 3 iso-butyl-1-methyl-xanthine, Sigma cat. No. 
i5879, Mw = 222.24 
 
RNA isolation Kit:  
 RNeasy® Micro Kit: QIAGEN cat. No. 74004 
 RNeasy® MIni Kit: QIAGEN cat. No. 74104 
 
 
 
 
 
qPCR analysis 
 See Primers Table 5 
 SYBRgreen, BIO-RAD cat. No. 1725006 
 Hard-Shell® 384-Well PCR plates, BIORAD cat. 
No. HSP-3805 
 
FACS analysis 
 See list of Abs Table 6 
 7-ADD: BD Biosciences, cat. No. 559925 
 
Others 
 Alexa Fluor 488 azide: Invitrogen, cat. No. 
A10266, MW=861.04 
 EdU, 5-Ethynyl-2′-deoxyuridine SIGMA cat.no. 
T511285-5MG 
 MTT, Thiazolyl Blue Tetrazolium, Sigma cat. No. 
M5655-1G 
 DAPI: Sigma, cat. No. D9542 
 Sequencing Kit: ABI PRISM BigDye Terminator 
v3.1 Ready Reaction Cycle Sequencing Kit, 
Applied Biosystems cat.no. 4337455; 5x 
Sequence buffer cat. No. 4336697 
 iSCript™ cDNA Synthesis Kit, BIORAD cat. No. 
170-8890 
 Alizarine Red SIGMA cat. NO. A5533-25G 
 Oil-Red-O SIGMA cat. NO. O0625-25G 
 
Plastic 
 Culture plates: T-75 Flask, Grenier Bio-one cat. 
No. 658175; 6wells plates, Grenier Bio-one cat. 
No. 657160; 96wells plate Grenier Bio-one cat. 
No. 655180.  
 Tubes: 50mL Grenier Bio-one, cat. No. 227261; 
15mL Grenier Bio-one, cat. No. 186161 
 70µm cell strainer, BD Biosciences cat. No. 
352350  
 Millex® Syringe Filter Units, Sterile, Millipore cat. 
No. SLGV033RS 
 Cryogenic Vial (2mL), Corning cat. No. 430488 
 10mL pipettes, Grenier Bio-one cat. No. 607180 
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